<SEC-DOCUMENT>0001193125-24-221775.txt : 20240919
<SEC-HEADER>0001193125-24-221775.hdr.sgml : 20240919
<ACCEPTANCE-DATETIME>20240919074539
ACCESSION NUMBER:		0001193125-24-221775
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20240919
DATE AS OF CHANGE:		20240919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cibus, Inc.
		CENTRAL INDEX KEY:			0001705843
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE CHEMICALS [2870]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				271967997
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273062
		FILM NUMBER:		241309116

	BUSINESS ADDRESS:	
		STREET 1:		6455 NANCY RIDGE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 450-0008

	MAIL ADDRESS:	
		STREET 1:		6455 NANCY RIDGE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Calyxt, Inc.
		DATE OF NAME CHANGE:	20170504
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d885907d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)<BR>Registration No. 333-273062 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>To Prospectus, dated October&nbsp;27, 2023 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g885907g57l88.jpg" ALT="LOGO" STYLE="width:2.53184in;height:0.614497in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>3,000,000 Shares of Class&nbsp;A Common Stock </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Cibus, Inc. (&#147;Cibus,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148;) is offering 3,000,000 shares of
its Class&nbsp;A common stock, $0.0001 par value per share (&#147;Class&nbsp;A Common Stock&#148;), pursuant to this prospectus supplement and the accompanying prospectus. We have granted the underwriters the option to purchase, exercisable within a
45-day period, up to an additional 450,000 shares of Class&nbsp;A Common Stock. We are offering all of the shares of Class&nbsp;A Common Stock offered by this prospectus on a firm commitment underwritten basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The Company&#146;s Chief Executive Officer, Rory Riggs, is purchasing 250,000 shares in this offering at the public offering price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The Class&nbsp;A Common Stock is listed on the Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;CBUS.&#148; On
September&nbsp;16, 2024, the last reported sale price of the Class&nbsp;A Common Stock on Nasdaq was $5.15 per share. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:11pt; font-family:Times New Roman"><B>Investing in
our securities involves a high degree of risk. Before making an investment decision, please read the information in the section titled &#147;<A HREF="#suprom885907_4">Risk Factors</A>&#148; beginning on page S-9 of this prospectus supplement and in
the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share&nbsp;of&nbsp;Class&nbsp;A<BR>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;<FONT STYLE="font-size:2pt">&#8195;</FONT>Total<FONT STYLE="font-size:2pt">&#8195;</FONT>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.1713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">513,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds, before expenses, to us<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.8287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,486,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">We have agreed to pay the underwriters underwriting discounts and commissions equal to (i) 7.0% of the
aggregate gross proceeds in this offering from the sale of securities to certain investors and (ii) 2.0% of the aggregate gross proceeds in this offering from the sale of securities to certain other investors and to the Company&#146;s Chief
Executive Officer. See &#147;Underwriting&#148; beginning on page S-19 for additional information regarding the compensation payable to the underwriters. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">If the underwriters exercise their option to purchase additional shares in full, the total underwriting
discounts and commissions payable by us will be $591,054, and the total proceeds to us, before expenses, will be $13,208,946. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman"><B>Neither the U.S.&nbsp;Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Delivery of the securities offered hereby is expected to be made on or about September&nbsp;19, 2024, subject to the satisfaction of certain
closing conditions. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><B>Roth&nbsp;Capital&nbsp;Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>A.G.P.</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is September&nbsp;18, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_8">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_9">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_10">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_10a">CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom885907_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_3">INFORMATION ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_8">DESCRIPTION OF DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_10">DESCRIPTION OF SUBSCRIPTION RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_11">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_15">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-273062)</FONT> that we filed with the Securities and Exchange Commission (the &#147;SEC&#148;) utilizing a &#147;shelf&#148; registration
process. This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information contained in the accompanying prospectus and the documents
incorporated by reference herein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a
conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should
rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in the
accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further
note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein or in the accompanying prospectus were made solely for the benefit of the
parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or
covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with information that is different from the information contained or incorporated by reference in
this prospectus supplement or the accompanying prospectus and any free writing prospectus prepared by or on our behalf to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other
information others may give you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this prospectus supplement or the accompanying prospectus, or incorporated
by reference herein or therein, or in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement
and the accompanying prospectus or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since those dates. It is important for you to read and consider all information contained in
this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we have
referred you in the sections entitled &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement and in the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering to sell, and seeking offers to buy, the shares of Class&nbsp;A Common Stock offered by this prospectus supplement only in
jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of such securities offered by this prospectus supplement in certain jurisdictions may be restricted
by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of Class&nbsp;A
Common Stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer
to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the documents incorporated by reference in this prospectus
supplement contain market data and industry statistics and forecasts that are based on independent industry publications, other publicly available information and our internal sources and estimates. Although we believe that third-party sources are
reliable, we do not guarantee the accuracy or completeness of the information extracted from these sources and we have not independently verified such information. Similarly, while we believe our management estimates to be reasonable, they have not
been verified by any independent sources. Although we are not aware of any misstatements regarding the market and industry data presented or incorporated by reference in this prospectus supplement, these estimates involve risks and uncertainties and
are subject to change based on various factors, including those discussed in the section titled &#147;Risk Factors&#148; in this prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that
are incorporated by reference into this prospectus supplement. Forecasts and other forward-looking estimates about our industry or our performance within our industry are subject to the risks and uncertainties regarding forward-looking statements
described under the caption &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; Accordingly, investors should not place undue reliance on this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights and supplements selected information, including information contained elsewhere in this prospectus supplement or
incorporated by reference in this prospectus supplement, and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus supplement and accompanying
prospectus, and any related free writing prospectus, including the risks of investing in our securities discussed in the section titled &#147;Risk Factors&#148; contained in this prospectus supplement and any related free writing prospectus, and
under similar headings in the other documents that are incorporated by reference into this prospectus supplement. You should also carefully read the information incorporated by reference into this prospectus supplement, including our financial
statements, and the exhibits to the registration statement of which this prospectus supplement is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview and Market Opportunity
Updates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits
(or specific genetic characteristics) in seeds. Our primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, <FONT
STYLE="white-space:nowrap">nutrient-use,</FONT> or the climate. These traits are referred to as productivity traits and drive greater farming profitability and efficiency. They do this in several ways, including, but not limited to, making plants
resistant to diseases or pests or enabling plants to process nutrients more efficiently. Certain of these traits lead to the reduction in the use of chemicals like fungicides, insecticides, or the reduction of fertilizer use, while others make crops
more adaptable to their environment or to climate change. The ability to develop productivity traits in seeds that can increase farming productivity and reduce the use of chemicals in farming is the promise of gene editing technologies. In addition,
we are developing, through partner-funded projects, certain alternative plant-based oils or <FONT STYLE="white-space:nowrap">bio-based</FONT> fermentation products to meet the functional needs of the new sustainable ingredients industry to replace
current ingredients that are identified to raise environmental challenges, such as ingredients derived from fossil fuels, materials that cause deforestation, or materials that raise other sustainability challenges. We remain open to partner-funded
program opportunities with our previously established platforms, such as flax, peanut, sugar beet, cassava and alfalfa. Cibus&#146; core technology is its propriety gene editing platform called the Rapid Trait Development System<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or <B><I>RTDS</I></B><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. It is the underlying technology in Cibus&#146; Trait
Machine<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> process: a standardized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> semi-automated high-throughput gene editing system that directly
edits seed companies&#146; elite germplasm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Update </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2023, Cibus implemented a strategic realignment to align with its primary commercial objective of advancing its late-stage
activities. In particular, Cibus is focusing its operations on completing the launch of its first three traits&#151;Pod Shatter Reduction (PSR), HT1 (Herbicide Tolerance), and HT3 (Herbicide Tolerance)&#151;in its crop programs in Canola, Winter
Oilseed Rape (WOSR), and Rice, enabling its Soybean platform, and advancing its <I>Sclerotinia</I> resistance trait and HT2 trait in Canola, WOSR, and Soybean. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company believes that this refocusing on Cibus&#146; strengths and highest priorities best positions it to meet its strategic objectives.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the strategic realignment, the Company initiated cost reduction initiatives designed to preserve capital resources for the
advancement of Cibus&#146; priority objectives, which initiatives include reductions in capital expenditures, streamlining of independent contractor utilization, and prioritization of near-term payment obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since initiating the October 2023 strategic realignment, the Company has continued to proactively assess further cost reduction opportunities,
including opportunities to further refine prioritization of the Company&#146;s </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
strategic objectives, to reduce operational expenditures outside of the Company&#146;s strategic priorities, and to otherwise optimize human capital resources and enhance operational efficiency.
Considering continuing capital resource constraints, the Company may implement one or more of such additional measures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background on the Plant
Genetics Industry </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plant genetics is the study of genes, genetic variation, and heredity specifically in plants, seeds, or
germplasm. Germplasm is the term used to describe the seeds, plants, or plant parts useful in plant breeding. The plant genetics industry consists of the activities, like breeding and genetics, that are focused on understanding and improving
germplasm. Plant genetics for germplasm and traits are the core technologies in seeds and ultimately, the varieties and parental lines of seed companies. These technologies underpin the expected performance of a given seed and are the primary basis
for competition in the seed business. These technologies are generally developed internally by seed companies, but they are often bought or licensed from third parties such as other seed companies or the many academic institutions that have large
plant genetics programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increasing yields, lowering costs, and making crop outcomes more predictable are the core targets of trait
development programs. Each of these targets has a readily quantifiable economic basis for determining the trait value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The targets
addressed by early <FONT STYLE="white-space:nowrap">GMO-based</FONT> traits were weed and insect management. Each of these had a material impact on farming productivity and sustainability. The Bt trait (an early GMO trait for insect resistance) is
an excellent example. It is used to control corn borers and is credited with materially increasing farming productivity both through improved yield and through material reduction in the use (and cost) of insecticides. A 2010 National Research
Council study concurred that Bt crops led to reduced pesticide use and /or the use of pesticides with lower toxicity compared to those used on conventional crops. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the underlying positive economics of the Bt trait, it is estimated by AgBioInvestor that the average trait fee paid by farmers for
the Bt traits is <FONT STYLE="white-space:nowrap">$10-$20</FONT> per acre, with aggregate trait fees estimated at approximately $2.6&nbsp;billion in corn, $0.7&nbsp;billion in cotton, and $0.5&nbsp;billion in soy. At this price, it is estimated that
the Bt trait is incorporated in the genetics of seeds that are planted on over 300&nbsp;million acres. The annual royalties associated with the Bt trait are estimated by AgBioInvestor to be approximately $4.0&nbsp;billion. It is further estimated by
AgBioInvestor that the <FONT STYLE="white-space:nowrap">GMO-based</FONT> weed management traits are also planted on over 300&nbsp;million acres and earn annual trait fees estimated to be greater than $3.5&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that novel traits or genetic characteristics in seeds will continue to be the driving force of the plant genetics industry and
the growth of the seed business. Given peak acres, there is increasing pressure on improved crop productivity to meet the growing demands for food and food security. The promise of the new gene editing industry is to be a key driver behind a new
generation of plant traits that can meet the current and future challenges of farming, in general, and climate change, specifically. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Breeding
Challenge that the Trait Machine Process Addresses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the introduction of desirable traits in plants was achieved by
major seed companies using conventional breeding or by employing transgenic processes. Both traditional breeding and transgenic bioengineering require substantial development time frames. According to a 2022 study from AgBioInvestor, the average
time to bring a biotechnology-derived genetic trait to the point of commercialization in 2017-2022 was approximately 16.5 years at a cost of $115.0&nbsp;million. Conventional breeding techniques, on the other hand, can require approximately <FONT
STYLE="white-space:nowrap">12-15</FONT> years. Further, for transgenic techniques, the integration of recombinant DNA typically results in seeds being classified as genetically engineered or bioengineered producing GMOs that are subject to strict
filings and specific GMO approvals prior to commercialization. Both methods produce genetic diversity in the genetic material (DNA) of plants: one through traditional breeding methods and the other by making precise changes to the plant&#146;s DNA
sequence through the use of tools such as CRISPR-Cas9. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trait Machine process transforms a lengthy and random conventional breeding process into
a timebound, reproducible, and predictable system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast, Cibus views gene editing as an extension of plant breeding. The Trait
Machine process provides an extension of conventional breeding that provides a standardized gene editing process that operates in an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> semi-automated system
that can achieve the identical changes as conventional breeding more precisely and efficiently. The Trait Machine process provides a process that enables plant gene editing to occur in a timebound, reproducible, and predictable process. Importantly,
it has the ability to develop the complex traits that are difficult to achieve using conventional breeding technologies. In addition, the Trait Machine process enables the introduction of high value traits directly into a customer&#146;s
market-ready varieties or parent lines in a process that takes on average 3 to 5 years. By working directly with a customer&#146;s elite germplasm, the Trait Machine process accelerates the time to market for developed traits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Trait Pipeline and Market Opportunity Updates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a pipeline of six productivity traits, four of which are applicable to multiple crops. Three of our traits are developed, meaning that
they have been validated in field trials, have been edited into the elite lines of seed company partners and have started &#147;shipping&#148;&#151;being transferred to these partners for <FONT STYLE="white-space:nowrap">pre-commercialization</FONT>
testing. These traits are pod shatter resistance (PSR) in Canola and two herbicide resistance traits (HT1 and HT3) in Rice. In addition, we have three advanced traits (i.e., where the editing process is underway with known edit targets) for
<I>Sclerotinia</I> resistance, HT2 (another novel broadleaf herbicide resistance trait), and nutrient use efficiency (&#147;NUE&#148;). Our primary commercial objective is advancing our three developed traits: PSR, HT1 and HT3 into customer
commercial lines in Canola (which we use to mean Canola, Carinata, Winter Oilseed Rape and Turnip Rape) and Rice, as further detailed below, and establishing an editing platform in Soybean with which Cibus can edit a customer&#146;s germplasm and
return it back to the customer. We also plan to subsequently develop traits in Wheat and Corn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the nature of our relationship
with seed companies, we refer to seed companies as &#147;customers&#148; when we agree to a collaboration process with the joint intent of commercializing the Cibus trait in the customer&#146;s germplasm. All collaboration processes begin with an
agreement on the material transfer of the customer&#146;s elite germplasm to us for editing and agreement on the specific edits to be performed. Collaboration processes with seed company customers are generally entered into after we have completed
validated field trials for the specific trait in the specific crop and the customer has positively reviewed the edited product and the validated field trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, we have certain customers for whom we have commercial contract terms. For others, commercial contract terms will generally be
agreed on when we return the customer&#146;s seed with our edit. In each case, there is an understanding that commercial terms are expected to be in line with common industry standards and referenced trait fee ranges based on the specific traits in
a specific crop and geography. With the exception of our <I>Sclerotinia</I> resistant trait, there is comparable reference market data and industry information for the trait fee for each trait. Although our <I>Sclerotinia</I> disease trait does not
have another disease trait to reference against, there are other traits such as the Bt traits for insect resistance for which market data and industry information provides ranges for determining trait fees as well as the cost of fungicide
application to manage the disease. The process for determining trait fees is well established in the industry and involves determining the economic value of specific trait and determining the sharing arrangement between the farmer, the seed company
customer and the trait developer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We added NUE in Canola to our trait portfolio during the second quarter of 2024. Our initial NUE trait
is expected to be part of a family of traits relevant to all crops that can make fertilizer use more efficient on a global basis, without compromising the yield that farmers expect. This NUE trait is also our first use of our Trait Machine process
to operationalize a third party developed and <FONT STYLE="white-space:nowrap">in-licensed</FONT> trait, demonstrating the Company&#146;s </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability as a development partner to take third party identified gene targets and successfully make edits in our platforms to develop a trait. Because NUE is not yet included in the Company&#146;s
core commercial pipeline, we have not yet disclosed potential royalty estimates in our target markets for this trait. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Canola </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the total market for Canola consists of approximately 50&nbsp;million acres of crop across North America (&#147;NA&#148;), the
European Union (&#147;EU&#148;), the United Kingdom, Ukraine, and Australia. The chart below summarizes information relating to our pipeline traits for Canola, including our beliefs with respect to the potential royalties available for Canola in our
target market: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trait</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage of<BR>Development</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years<BR>of Field<BR>Trials<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;from<BR>Edit to<BR>Initial&nbsp;Field<BR>Trials</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Accessible<BR>Acres<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Trait Fee<BR>(per&nbsp;acre)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Potential&nbsp;Target<BR>Market<BR>Royalties<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Geography</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PSR</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Developed</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">28&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$&#8199;5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$142&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">NA/EU</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Sclerotinia</I>&nbsp;resistance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Advanced</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">30&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$300&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">NA/EU</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HT2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Advanced</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">20&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$&#8199;5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$100&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">NA/EU</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">78&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$542&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Following greenhouse trait validation, field trials are generally conducted using customer-specific germplasm
lines. &#147;Years of Field Trials&#148; indicate field trial years in which crop progressed to physiological maturity. <I>Sclerotinia</I> resistance is a multi-mode of action trait, meaning that the trait operates through gene edits addressing
multiple cellular processes or physiologies that are affected by the disease. For <I>Sclerotinia</I> resistance, years from edit to initial field trial is measured for each mode of action as an independent trait with this chart presenting
measurement for Canola in respect of the initial mode of action. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">&#147;Accessible Acres&#148; represent management&#146;s estimate of the number of total acres for the specified
geography on which seed with the specified Cibus trait would be planted, which is based on industry sources or references regarding the need for a specific trait in the specific crop and geography or specific jurisdiction, taking into account
assumptions about competition, trait relevance, switching costs and adoption timeframes, and various other factors. Among other assumptions, management includes EU acres in determining Accessible Acres. However, access to EU acreage is dependent
upon a favorable outcome of the EU legislative process with respect to a currently pending proposal. There can be no assurance that such a favorable outcome will be achieved. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">&#147;Trait Fees&#148; represent management&#146;s assumption regarding the potential per acre fee that may be
received by Cibus in respect of the applicable trait, taking into account available market information regarding competitors&#146; current trait fees as well as assumptions regarding competition, trait relevance and trait value in specific
geographies and potential savings to farmers, switching costs, and various other factors. Trait fees are divided between the trait company and the seed company, with the percent of the fee that accrues to the trait developer varying depending on the
type of trait, value, and intellectual property protection. Because <I>Sclerotinia</I> resistance is expected to be the first commercial disease trait, there are no directly comparable trait fee reference points. Management estimates that the
<I>Sclerotinia</I> resistance trait fee will generally align with the relevant cost of fungicide applications, which are an alternative method to manage disease. See&nbsp;the discussion of <I>Sclerotinia</I> trait fees above. For the remaining trait
fees, management also takes into account comparable trait fees currently payable in respect of seeds containing existing commercial traits. Actual Target Market Royalties, if any, could be materially different than those expressed, implied, or
anticipated by the estimates presented. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">&#147;Estimated Potential Target Market Royalties&#148; represents (i)&nbsp;management&#146;s estimates of
Accessible Acres, times (ii)&nbsp;management&#146;s estimate of the Trait Fee for the specific trait for a specific crop in a specific geography. These figures are calculated based on management estimates and assumptions, which are based on industry
references and estimates of key data, such as the number of acres or percentage of total acres for which the trait would be relevant or where the applicable crop is impacted such that it would benefit from a specific trait. In each crop for each
trait, the Accessible Acres may vary widely based on the trait, crop, geography, or need. Cibus&#146; estimates of potential target market royalties also serves as the Company&#146;s estimate of its peak sales for the specific trait and specific
crop. This peak would generally be projected to occur several years after commercial availability of seed containing the applicable trait. Accordingly, such calculations should be considered illustrative. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Calculated based on an estimate of Accessible Acres within a Total Canola Market of approximately
50&nbsp;million total Canola acres in North America (24.2&nbsp;million acres), Europe (including the EU (15.3&nbsp;million acres), the United Kingdom (0.9&nbsp;million acres), and Ukraine (2.5&nbsp;million acres)), and Australia (6.5&nbsp;million
acres), obtained from (i)&nbsp;Eurostat, the statistical office of the EU (&#147;Eurostat&#148;), (as of 2023, with respect to the EU), (ii) the United Kingdom&#146;s Department for Environment Food&nbsp;&amp; Rural Affairs (&#147;DEFRA&#148;) (as
of 2022, with respect to the United Kingdom), and (iii)&nbsp;the Food and Agriculture Organization of the United Nations (&#147;FAO&#148;) (as of 2021, with respect to Australia, North America, and Ukraine). Potential Target Market Royalties is
based on the Company&#146;s estimate of Accessible Acres and Trait Fees. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have ten customers for its PSR
and/or <I>Sclerotinia</I> resistance traits. The eight customers advancing our PSR trait in Canola represent approximately 16&nbsp;million customer Accessible Acres and approximately $80&nbsp;million in potential initial customer royalties for this
trait. This calculation of potential initial customer royalties for our PSR trait is based on the estimated total number of Canola acres planted with seed sold by these Cibus customers. The calculation assumes 16&nbsp;million acres for which
Cibus&#146; PSR trait fee will apply (i.e., on all of these customers&#146; Canola acres) and a potential trait fee of approximately $5 per acre. For our PSR trait, four edited germplasm lines have been transferred back to three unique customers
(two in 2023 and two in 2024 to date) and additional lines are currently ready to transfer back to seven customers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rice </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the market for Rice includes approximately 15&nbsp;million acres of crop across North America, Latin America and Europe
(including the EU and <FONT STYLE="white-space:nowrap">non-EU</FONT> countries, such as Russia and Ukraine). Based on discussions with customers and other market participants, we currently anticipate that our HT1 and HT3 traits will&nbsp;primarily
be utilized as stacked traits within an integrated weed management platform, although in some circumstances there may be more limited opportunities for HT1 or HT3 to be utilized on a <FONT STYLE="white-space:nowrap">stand-alone</FONT> basis.
Accordingly, given our current focus on market demand for such an integrated weed management solution, we are evaluating the market opportunity on this basis. The chart below summarizes information relating to our pipeline traits for Rice, including
our beliefs with respect to the potential royalties available for Rice in our target market: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trait</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage of<BR>Development</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years of Field<BR>Trials<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;from<BR>Edit to<BR>Initial&nbsp;Field<BR>Trials</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Accessible<BR>Acres<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Trait Fee<BR>(per&nbsp;acre)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Potential&nbsp;Target<BR>Market<BR>Royalties<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal Geography</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Weed Management Platform (HT1/HT3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-size:9.5pt">Developed</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-size:9.5pt">5(HT1)/2(HT3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-size:9.5pt">3</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-size:9.5pt">9&nbsp;million</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-size:9.5pt"><FONT STYLE="white-space:nowrap">~$20-40</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-size:9.5pt">$200&nbsp;million<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-size:9.5pt">U.S./South&nbsp;America</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$200&nbsp;million<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See note 1 to the &#147;Canola&#148; table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See note 2 to the &#147;Canola&#148; table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See note 3 to the &#147;Canola&#148; table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See note 4 to the &#147;Canola&#148; table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Calculated based on an estimate of Accessible Acres within a Total Rice Market of approximately 15&nbsp;million
total Rice acres in North America (2.5&nbsp;million acres), Latin America (10.8&nbsp;million acres), and Europe (including the EU and <FONT STYLE="white-space:nowrap">non-EU</FONT> countries, such as Russia and Ukraine) (1.5&nbsp;million acres),
each obtained from the FAO (as of 2021). Potential Target Market Royalties is based on the Company&#146;s estimate of Accessible Acres and Trait Fees. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Represents a blended total estimate of the potential target market royalties to be received, assuming HT1 is
primarily sold as an adjunct to HT3. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreements with, and have received the elite germplasm of, four leading
rice seed companies in the United States and Latin America. Together, it is estimated that these four companies represent approximately 45% of all Accessible Acres for our weed management platform in North America and Latin America, or approximately
4.0&nbsp;million customer Accessible Acres and over $100&nbsp;million in potential initial customer royalties. This calculation of potential initial customer royalties is based on the estimated total number of Rice acres planted with seed sold by
our customers that we consider Accessible Acres. The calculation assumes 4.0&nbsp;million acres for which our trait fee </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will apply and a potential trait fee of between $20 to $40 per acre in the specific geography. The initial edit for these traits was returned to one customer during 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we believe that the market for Rice includes over 175&nbsp;million acres of crop across key countries in Asia (India, Bangladesh,
Pakistan, Philippines and Thailand), and that there are a total of 75&nbsp;million Accessible Acres for our herbicide platform in Rice in that geography. We believe that the estimated Trait Fee per Acre in this geography is approximately $2 to $3,
yielding approximately $150&nbsp;million in Potential Target Market Royalties. The regulatory landscape across Asia is substantially less developed and less uniform than in the United States, Latin America and Europe. Accordingly, our ability to
access acres in Asia may be highly variable and require additional regulatory compliance on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Soybean </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently in the process
of developing an editing platform for soybean. Our soybean single-cell regeneration platform is now expected to be operational, and have initial editing completed, in 2024. We have received the elite germplasm of one customer for potential editing
once the soybean platform is operational. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the total market for Soybean consists of approximately 250&nbsp;million acres
of crop across North America, Latin America and Europe (including the EU, Albania, North Macedonia, the Republic of Moldova, Russia and Ukraine). The chart below summarizes information relating to our pipeline traits for Soybean, including our
beliefs with respect to the potential royalties available for Soybean in our target market: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trait</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage of<BR>Development</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years of Field<BR>Trials</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;from<BR>Edit to<BR>Initial&nbsp;Field<BR>Trials</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Accessible<BR>Acres<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Trait Fee<BR>(per&nbsp;acre)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Potential&nbsp;Target<BR>Market<BR>Royalties<SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Geography</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><I>Sclerotinia</I>&nbsp;resistance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Advanced</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Awaiting&nbsp;Platform</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8199;50&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$500&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">U.S./Brazil</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">HT2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Advanced</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Awaiting Platform</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8199;75&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">~$&#8199;5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$375&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">U.S./Brazil</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">125&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$875&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See note 2 to the &#147;Canola&#148; table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See note 3 to the &#147;Canola&#148; table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">See note 4 to the &#147;Canola&#148; table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Calculated based on an estimate of Accessible Acres within Total Soybean Market of approximately
250&nbsp;million total Soybean acres in North America (91.6&nbsp;million acres), Latin America (153.0&nbsp;million acres), and Europe (including the EU (2.5&nbsp;million acres) and Ukraine (3.3&nbsp;million acres)), obtained from Eurostat (as of
2023, with respect to the EU) and from the FAO (as of 2021, with respect to North America, Latin America, and the Ukraine). Potential Target Market Royalties is based on the Company&#146;s estimate of Accessible Acres and Trait Fees.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> Corporate Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a holding company with substantially all of our assets and operations conducted through Cibus Global, LLC (&#147;Cibus Global&#148;) and
its subsidiaries. Our sole material asset consists of our interest in Cibus Global. We are the sole managing member of Cibus Global and are responsible for all operational, management and administrative decisions relating to Cibus Global&#146;s
business and consolidate the financial results of Cibus Global and its subsidiaries. Owners of Cibus Global&#146;s Common Units (&#147;Cibus Global Common Units&#148;) other than us own a corresponding number of shares of our Class&nbsp;B common
stock, par value $0.0001 per share (the &#147;Class&nbsp;B Common Stock&#148; and, together with the Class&nbsp;A Common Stock, the &#147;Common Stock&#148;), which have voting (but no economic) rights with respect to Cibus, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A
Common Stock trades on Nasdaq under the symbol &#147;CBUS.&#148; Our principal executive offices are located at 6455 Nancy Ridge Drive, San Diego, CA 92121 and our telephone number is (858) <FONT STYLE="white-space:nowrap">450-0008.</FONT> Our
filings with the SEC are posted on our corporate website at www.cibus.com. The information found on our website is not part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A Common Stock Offered by Us</B> </P></TD>
<TD>3,000,000 shares of Class&nbsp;A Common Stock. We have granted the underwriters the right to purchase, exercisable within a 45-day period, up to an additional 450,000 shares of Class&nbsp;A Common Stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Offering Price</B> </P></TD>
<TD>The offering price for each share of Class&nbsp;A Common Stock is $4.00. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Shares Outstanding Immediately After this Offering </B> </P></TD>
<TD>26,015,417 shares of Class&nbsp;A Common Stock (or 26,465,417 shares of Class&nbsp;A Common Stock if the underwriters fully exercise their option to purchase additional shares of Class&nbsp;A Common Stock) and 3,112,516 shares of Class&nbsp;B
Common Stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Insider Participation</B><B></B> </P></TD>
<TD><B></B>The Company&#146;s Chief Executive Officer, Rory Riggs, is purchasing 250,000 shares in this offering at the public offering price. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B><B></B> </P></TD>
<TD><B></B>We estimate that net proceeds from this offering will be approximately $11.1 million (or approximately $12.8 million if the underwriters fully exercise their option to purchase additional shares of Class&nbsp;A Common Stock), after
deducting underwriting discounts and commissions and our estimated expenses related to the offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently intend to use the net proceeds from this offering to fund further development of new and improvement of existing seed traits, Trait Machine operations, and for working capital and general corporate
purposes. See the section titled &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors</B><B></B> </P></TD>
<TD><B></B>Investment in our securities involves a high degree of risk. You should read the section titled &#147;Risk Factors&#148; in this prospectus supplement and in the documents incorporated by reference into this prospectus supplement for a
discussion of factors to consider before deciding to purchase our securities offered in this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital Market Symbol</B><B> </B></P></TD>
<TD><B></B>The Class&nbsp;A Common Stock is traded on Nasdaq under the symbol &#147;CBUS.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of Shares to be
outstanding after this offering is based on 23,015,417 shares of Class&nbsp;A Common Stock and 3,112,516 shares of Class&nbsp;B Common Stock outstanding as of June&nbsp;30, 2024 and excludes as of that date: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">469,095 shares of restricted Class&nbsp;A Common Stock, which are subject to vesting conditions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">150,899 shares of Class&nbsp;A Common Stock issuable upon the exercise of outstanding stock options with a
weighted average exercise price of $270.66 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">115,541 shares of Class&nbsp;A Common Stock issuable upon the vesting and settlement of restricted stock units
outstanding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,960,288 shares of Class&nbsp;A Common Stock reserved for future issuance under the Cibus, Inc. 2017 Omnibus
Plan, as amended (the &#147;Plan&#148;), including those anticipated to be issued in the future pursuant to a Company-wide &#147;staking grant&#148;; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">158,483 shares of Class&nbsp;A Common Stock issuable upon exercise of outstanding warrants to purchase
Class&nbsp;A Common Stock issued in February 2022 (&#147;2022 Common Warrants&#148;), each with an exercise price of $69.04 per share of Class&nbsp;A Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">50,000 shares of Class&nbsp;A Common Stock issuable upon exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Class&nbsp;A Common Stock issued in December 2023&nbsp;(&#147;2023 <FONT STYLE="white-space:nowrap">Pre-Funded&nbsp;Warrants&#148;),</FONT> each with an exercise price of $0.01
per share of Class&nbsp;A Common Stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,298,040 shares of Class&nbsp;A Common Stock issuable upon exercise of outstanding warrants to purchase
Class&nbsp;A Common Stock issued in June 2024&nbsp;(&#147;2024 Common&nbsp;Warrants&#148; and, together with the 2022 Common Warrants and the 2023 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the &#147;Warrants&#148;), each with an
exercsie price of $10.00 per share of Class&nbsp;A Common Stock (or $10.07 per share of Class&nbsp;A Common Stock in respect of 2024 Common Warrants issued to the Company&#146;s Chief Executive Officer). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, information in this prospectus supplement assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no further exercise of outstanding options or Warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of the underwriters&#146; option to purchase up to an additional
450,000&nbsp;shares of Class A Common Stock from us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no future issuances by us of shares of our Class&nbsp;A Common Stock or securities convertible into or
exercisable for our Class&nbsp;A Common Stock, including as part of any future offerings of such securities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should consider carefully the risks described below and those risk factors described under the heading &#147;Item 1.A. Risk
Factors&#148; in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023, as may be updated by our subsequent filings under the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), that are incorporated by reference in this prospectus supplement in their entirety, together with other information in this prospectus supplement and the information and documents incorporated by reference in
this prospectus supplement and any free writing prospectus that we may authorize for use in connection with this offering before you make a decision to invest in our securities. If any of these risks actually occur, our business, operating results,
prospects or financial condition could be harmed. This could cause the trading price of the Class&nbsp;A Common Stock to decline and you may lose all or part of your investment. The risks below and incorporated by reference in this prospectus
supplement are not the only ones we face. Additional risks not currently known to us or that we currently deem immaterial may also affect our business operations. Please also read carefully the section below titled &#147;Cautionary Note Regarding
Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of Class&nbsp;A Common Stock in this offering, you will experience immediate dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price of the Class&nbsp;A Common Stock exceeds the net tangible book value per share of Class&nbsp;A Common Stock as of
June&nbsp;30, 2024, before giving effect to this offering. Accordingly, purchasers of shares of Class&nbsp;A Common Stock in this offering will incur immediate dilution of approximately $9.81 per share of Class&nbsp;A Common Stock, representing the
difference between the offering price of $4.00 per share of Class&nbsp;A Common Stock and our as adjusted net tangible book value per share as of June&nbsp;30, 2024, after giving effect to this offering. For a further description of the dilution
that you will experience immediately after this offering, see the section in this prospectus supplement entitled &#147;Dilution&#148; beginning on page S-17. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to continue as a going concern will depend on our ability to obtain additional financing in the near term. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024, we had $30.0&nbsp;million of cash and cash equivalents. Current liabilities were $29.0&nbsp;million as of
June&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if this offering is successful, there will continue to be substantial doubt about our ability to continue as a
going concern in the absence of additional financing. To finance our continued operations under our current business plan over the next 12 months, we will need to raise additional capital, including after giving effect to this offering. Such
financing may not be available within our required timeframes, on acceptable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the foregoing needs and
constraints on our capital resources, a special committee of our Board of Directors is evaluating a full range of strategic alternatives to maximize shareholder value, which may include potential equity or debt financing transactions, business
combination transactions (including an acquisition or merger transaction), sales of assets, licensing or other strategic transactions. Certain potential strategic transaction alternatives could (i)&nbsp;result in substantial additional dilution to
existing stockholders, (ii)&nbsp;result in the issuance of securities with preferences over our Common Stock, (iii)&nbsp;subject us to covenants that impose operational restrictions, (iv)&nbsp;require us to relinquish potentially valuable rights to
pipeline traits or proprietary technologies, (v)&nbsp;result in the granting of licenses on terms that are not favorable to us, or (vi)&nbsp;have a material adverse effect on the market price of the Class&nbsp;A Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on October&nbsp;18, 2023, we implemented a strategic realignment pursuant to which we initiated cost reduction initiatives
designed to preserve capital resources for the advancement of our priority objectives, which initiatives included reductions in capital expenditures, streamlining of independent contractor utilization, and prioritization of near-term payment
obligations. Our management has continued to proactively assess further cost reduction opportunities in view of current constraints and may implement one or more of such additional measures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to obtain substantial funding or consummate a strategic transaction in the next
several months and are unable to continue as a going concern, we may be required to discontinue or delay one or more of our development programs or to wind-down our business through the initiation of bankruptcy proceedings. In the event of a
wind-down, it is likely that holders of our Class&nbsp;A Common Stock, including investors in this offering, will lose all or part of their investment. If we seek additional financing to fund our business activities in the future and there is
substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of shares of our Class&nbsp;A Common Stock result in dilution to our stockholders. In order to raise additional capital, we expect to
offer additional shares of Class&nbsp;A Common Stock or other securities convertible into or exchangeable for Class&nbsp;A Common Stock, including sales of Class&nbsp;A Common Stock pursuant to a sales agreement between the Company and Stifel,
Nicolaus&nbsp;&amp; Company, Incorporated (&#147;Stifel&#148;), pursuant to which we may, from time to time, sell shares of our Class&nbsp;A Common Stock having an aggregate offering price of up to $80.0&nbsp;million through Stifel, as the
Company&#146;s sales agent, in an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offering (the &#147;ATM Facility&#148;), under which approximately $62.7&nbsp;million of availability remained at
June&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to sales of Class&nbsp;A Common Stock made pursuant to the ATM Facility, we expect in the future to seek
to raise additional equity financing, including through the offer of additional shares of Class&nbsp;A Common Stock or other securities convertible into or exchangeable for Class&nbsp;A Common Stock. Moreover, such additional equity offerings may
occur in the near term following this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that we will be able to sell shares or other securities in any other
offering at a price per share that is equal to or greater than the price paid by investors in this offering for a share of Class&nbsp;A Common Stock and investors purchasing shares or other securities in the future could have rights superior to
existing stockholders. The price per share at which we sell additional shares of Class&nbsp;A Common Stock or other securities convertible into or exchangeable for Class&nbsp;A Common Stock in future transactions may be higher or lower than the
price per share of Class&nbsp;A Common Stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if outstanding options or Warrants are exercised, you could
experience further dilution. As of June&nbsp;30, 2024, approximately 6,845,767 shares of Class&nbsp;A Common Stock are either issuable upon conversion of shares of Class&nbsp;B Common Stock, issuable upon exercise of outstanding options, issuable
upon vesting and settlement of outstanding restricted stock units, issuable upon exercise of outstanding Warrants or reserved for future issuance under the Plan and are eligible for sale in the public market to the extent permitted by the provisions
of various vesting schedules. Moreover, in the event that <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercised, we will not receive any meaningful amount of additional funds upon such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our large stockholders sell a substantial number of shares of Class&nbsp;A Common Stock in either the private or public markets, the market
price of the Class&nbsp;A Common Stock could decrease materially. The perception in the public market that these stockholders might sell Class&nbsp;A Common Stock could also depress the market price of the Class&nbsp;A Common Stock and could impair
our future ability to obtain capital, especially through an offering of equity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, shares of Class&nbsp;A Common
Stock issued or issuable under our equity incentive plans to employees and directors have been registered on Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration statements and may be freely sold in the public market upon issuance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways that
increase the value of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion to use the net proceeds from this offering, and
you will be relying on the judgment of our management regarding the application of these proceeds. You will not have the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opportunity to influence our decisions on how to use the proceeds, and we may not apply the net proceeds of this offering in ways that increase the value of your investment. Because of the number
and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our
business. Pending their use, we intend to invest the net proceeds from this offering in marketable securities that may include investment-grade interest-bearing securities, money market accounts, certificates of deposit, commercial paper and
guaranteed obligations of the U.S. government in accordance with our investment policy. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance
stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not paid dividends in
the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of the Class&nbsp;A Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never paid dividends and do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our
earnings, capital requirements, financial condition, prospects and other factors our board of directors may deem relevant. If we do not pay dividends, the Class&nbsp;A Common Stock may be less valuable because a return on your investment will only
occur if the price per share of Class&nbsp;A Common Stock appreciates and you sell the Class&nbsp;A Common Stock thereafter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Ownership of Class&nbsp;A Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of the Class&nbsp;A Common Stock has been and could remain volatile, which could
adversely affect the market price of the Class&nbsp;A Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price the Class&nbsp;A Common Stock has
experienced, and may continue to experience, volatility in response to various factors. Between the closing date of our merger with Cibus Global on May&nbsp;31, 2023 and September&nbsp;16, 2024, the closing price of the Class&nbsp;A Common Stock on
the Nasdaq Capital Market fluctuated from a high of $31.50 per share to a low of $4.45 per share. Some factors that may cause the market price of the Class&nbsp;A Common Stock to fluctuate include our quarterly operating results, our perceived
prospects or the perceptions of the market of our pipeline, new products or technologies, changes in securities analysts&#146; recommendations or earnings estimates and our ability to meet such estimates, changes in general conditions in the economy
or the financial markets, capital raising activity and other developments affecting us or our competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other market and
industry factors may cause the market price and demand for the Class&nbsp;A Common Stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their Class&nbsp;A Common
Stock at a favorable price or at all and may otherwise negatively affect the liquidity of the Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry
analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our Class&nbsp;A Common Stock, the price of the Class&nbsp;A Common Stock and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for the Class&nbsp;A Common Stock will be influenced by the research and reports that industry or securities analysts
publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or the performance of the Class&nbsp;A Common Stock, or if our operating results
fail to meet the expectations of analysts, the price of the Class&nbsp;A Common Stock would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial
markets, which in turn could cause the price of the Class&nbsp;A Common Stock or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this prospectus supplement contains or incorporates by reference information that includes or is based upon
&#147;forward-looking statements&#148; within the meaning of the federal securities laws, including Section&nbsp;27A of the Securities Act of 1933 and the rules and regulations promulgated thereunder (the &#147;Securities Act&#148;) and
Section&nbsp;21E of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe the expectations reflected in the forward-looking statements are reasonable, we
cannot guarantee future results, level of activity, performance or achievements. In some cases, you can identify these statements by forward-looking words such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plans,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;scheduled,&#148; &#147;should,&#148; &#147;targets,&#148;
&#147;will,&#148; &#147;would,&#148; or the negative of these terms and other similar terminology. Forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include statements about our future financial
performance, including our liquidity and capital resources, cash runway, and ability to continue as a going concern; the advancement, timing and progress of our platform development and trait development in crop platforms; the anticipated timing for
the presentation of data related to trait development and other operational activities; the timeframes for transferring traits in customers&#146; elite germplasm; the timeframe for commercialization of germplasm with our traits by seed company
customers; the timing for, and degree of, adoption by farmers of germplasm with our traits following commercialization; the capacity of our productivity traits to deliver competitive yield improvements; the ability of gene editing to address climate
change at scale; the timing and nature of regulatory developments relating to gene editing; the market opportunity for our plant traits, including the number of addressable acres, and the trait fees that we expect to receive; and our ability to
enter into and maintain significant customer collaborations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are important factors that could cause our actual results, level of
activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including, without limitation, factors relating to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need for additional near term funding to finance our activities and challenges in obtaining additional
capital on acceptable terms, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in expected or existing competition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges to our intellectual property protection and unexpected costs associated with defending intellectual
property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased or unanticipated time and resources required for our platform or trait product development efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties in connection with our development activities and for commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges associated with our ability to effectively license our productivity traits and sustainable ingredient
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that farmers do not recognize the value in germplasm containing our traits or that farmers and
processors fail to work effectively with crops containing our traits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or disruptions in our platform or trait product development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges that arise in respect of our production of high-quality plants and seeds cost effectively on a large
scale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our dependence on distributions from Cibus Global to pay taxes and cover our corporate and overhead expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments that disfavor or impose significant burdens on gene editing processes or products;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and uncertainties regarding regulatory developments, particularly in the European Union;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve commercial success; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commodity prices and other market risks facing the agricultural sector; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological developments that could render our technologies obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impacts of our headcount reductions and other cost reduction measures, which may include operational and
strategic challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising
interest rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity
challenges on our ability to execute on our business plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any litigation related to the Merger Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our assessment of the period of time through which our financial resources will be adequate to support
operations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other important risks and uncertainties described in &#147;Item 1A. Risk Factors&#148; in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which was filed with the SEC on March&nbsp;21, 2024, as they may be updated or supplemented from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> in our
subsequent reports on Forms <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all
potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the
forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on our consolidated
financial condition, results of operations or liquidity. Therefore, you should not rely on any of these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of the risks or uncertainties described in this prospectus supplement occur, or should underlying assumptions prove
incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. All forward-looking statements, expressed or implied, included in this prospectus supplement are expressly qualified in their
entirety by this cautionary statement. This cautionary statement should also be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. Any forward-looking statement
made by us in this prospectus supplement is based only on information currently available to us and speaks only as of the date hereof. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements after
the date of this prospectus supplement, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement together with the documents we have filed with the SEC that are incorporated by reference and any
free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we currently expect. We qualify all of the
forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds we receive from this offering will be approximately $11.1&nbsp;million (or approximately $12.8&nbsp;million
if the underwriters fully exercise their option to purchase additional shares of Class&nbsp;A Common Stock) after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from the offering to fund further development of new and improvement of existing seed traits,
Trait Machine operations, and for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not determined the amounts that we plan to
spend on any specific area or the timing of such expenditures. Accordingly, our management will have broad discretion to use the net proceeds from this offering. Pending our use of the net proceeds from this offering, we intend to invest the net
proceeds in marketable securities that may include investment-grade interest-bearing securities, money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government in accordance with our investment
policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to invest in our
business and do not expect to pay any dividends in the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital
requirements and general business conditions and other factors that our board of directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_8"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our total number of authorized
shares of capital stock consists of (i) 210,000,000 shares of Class&nbsp;A Common Stock, (ii) 90,000,000 shares of Class&nbsp;B Common Stock, and (iii) 10,000,000 shares of preferred stock, par value of $0.0001 per share (&#147;Preferred
Stock&#148;). As of June 30, 2024, we had outstanding 23,015,417 shares of Class&nbsp;A Common Stock (excluding 469,095 restricted shares of Class&nbsp;A Common Stock, which remain subject to vesting), 3,112,516 shares of Class&nbsp;B Common Stock
and no shares of Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A Common Stock is listed on Nasdaq under the symbol &#147;CBUS&#148;. The transfer agent and registrar for the Class&nbsp;A
Common Stock is Broadridge Corporate Issuer Solutions, LLC. The transfer agent&#146;s address is 1155 Long Island Avenue, Edgewood, NY 11717. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material terms of the Class&nbsp;A Common Stock are described under the heading &#147;Description of Capital Stock&#148; in the
accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in this offering, your ownership interest will be diluted to the extent of the difference between the offering price per share
of Class&nbsp;A Common Stock and the as adjusted net tangible book value per share of our Class&nbsp;A Common Stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net tangible book value (deficit) as of June&nbsp;30, 2024 was $(162.3)&nbsp;million, or $(7.05) per share. Net tangible book value
(deficit) per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of Class&nbsp;A Common Stock outstanding as of June&nbsp;30, 2024. Dilution in net tangible book value (deficit) per share of
Class&nbsp;A Common Stock represents the difference between the amount per share paid by purchasers of shares of Class&nbsp;A Common Stock in this offering and the as adjusted net tangible book value (deficit) per share of Class&nbsp;A Common Stock
immediately after giving effect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of 3,000,000&nbsp;shares of Class&nbsp;A Common Stock
in this offering by us at the offering price of $4.00 per share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us and assuming the underwriters do not exercise their option to purchase
additional shares of Class&nbsp;A Common Stock, our <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value (deficit) as of June&nbsp;30, 2024 would have been $(151.3)&nbsp;million, or $(5.81) per share. This represents an
immediate decrease in net tangible book deficit of $1.24 per share to existing stockholders and an immediate dilution of $9.81 per share to investors participating in this offering, as illustrated in the following table: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price per share of Class&nbsp;A Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value (deficit) per share as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.24</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value (deficit) per share as of June&nbsp;30, 2024, after giving
effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors purchasing Class&nbsp;A Common Stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above illustration assumes no exercise by the underwriters of the underwriters&#146; option to purchase up
to an additional 450,000 shares of Class&nbsp;A Common Stock from us, If the underwriters exercise their option in full to purchase 450,000 additional shares of Class&nbsp;A Common Stock in this offering, the as adjusted net tangible book value
(deficit) per share as of June&nbsp;30, 2024, after giving effect to this offering, would be $(5.65) per share and the dilution per share to investors purchasing Class&nbsp;A Common Stock in this offering would be $9.65 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 23,015,417 shares of Class A Common Stock outstanding as of June&nbsp;30, 2024, and excludes as of
that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">469,095 shares of restricted Class&nbsp;A Common Stock, which are subject to vesting conditions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">150,899 shares of Class&nbsp;A Common Stock issuable upon the exercise of outstanding stock options with a
weighted average exercise price of $270.66 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">115,541 shares of Class&nbsp;A Common Stock issuable upon the vesting and settlement of restricted stock units
outstanding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,960,288 shares of Class&nbsp;A Common Stock reserved for future issuance under the Plan, including those
anticipated to be issued in the future pursuant to a Company-wide "staking grant"; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">158,483 shares of Class&nbsp;A Common Stock issuable upon exercise of outstanding 2022 Common Warrants, each with
an exercise price of $69.04 per share of Class&nbsp;A Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">50,000 shares of Class&nbsp;A Common Stock issuable upon exercise of outstanding 2023 <FONT
STYLE="white-space:nowrap">Pre-Funded&nbsp;Warrants,</FONT> each with an exercise price of $0.01 per share of Class&nbsp;A Common Stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,298,040 shares of Class&nbsp;A Common Stock issuable upon exercise of outstanding 2024 Common&nbsp;Warrants,
each with an exercsie price of $10.00 per share of Class&nbsp;A Common Stock (or $10.07 per share of Class&nbsp;A Common Stock in respect of 2024 Common Warrants issued to the Company&#146;s Chief Executive Officer). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above illustration of dilution per share to investors participating in this offering assumes no further exercise of outstanding options or
Warrants and no future issuances by us of shares of our Class&nbsp;A Common Stock or securities convertible into or exercisable for our Class&nbsp;A Common Stock. To the extent that any outstanding options are exercised or other shares are issued
upon vesting of outstanding awards or otherwise, there will be further dilution to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_10"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an underwriting agreement with the several underwriters listed in the table below. Roth Capital Partners, LLC (&#147;Roth
Capital Partners&#148;) and A.G.P./Alliance Global Partners (&#147;A.G.P.&#148;) are the representatives of the underwriters. We refer to the several underwriters listed in the table below as the &#145;&#145;underwriters.&#146;&#146; Subject to the
terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and the underwriters have agreed to purchase from us, 3,000,000&nbsp;shares of our Class&nbsp;A Common Stock. Our Class&nbsp;A Common Stock trades on the
Nasdaq Capital Market under the symbol &#145;&#145;CBUS.&#146;&#146; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms and subject to the conditions contained in the
underwriting agreement, we have agreed to sell to the underwriters named below, and each underwriter severally has agreed to purchase from us, the respective number of shares of common stock set forth opposite its name below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares&nbsp;of<BR>Class&nbsp;A&nbsp;Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roth Capital Partners, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A.G.P./Alliance Global Partners</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligation of the underwriters to purchase the shares of
Class&nbsp;A Common Stock offered by this prospectus supplement and the accompanying prospectus is subject to certain conditions. The underwriters are obligated to purchase all of the shares of common stock offered hereby if any of the shares are
purchased. Roth Capital Partners and A.G.P. are acting as representatives of the underwriters, and expect to deliver the shares of Class&nbsp;A Common Stock to purchasers on or about September&nbsp;19, 2024, subject to the satisfaction of customary
closing conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the shares of Class&nbsp;A Common Stock directly to the investors at the applicable offering prices set forth
on the cover page of this prospectus supplement, and to dealers at that price less a concession not in excess of $0.14 per share of Class&nbsp;A Common Stock. After this offering, the offering price, concessions and other selling terms may be
changed by the underwriters. The shares of Class&nbsp;A Common Stock are offered subject to receipt and acceptance by the underwriters and to the other conditions, including the right to reject orders in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the compensation to be paid to the underwriters by us and the proceeds, before expenses, payable to us: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>of&nbsp;Class&nbsp;A<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With Option<BR>to Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">513,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">591,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,486,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,208,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to pay the underwriters underwriting discounts and commissions equal to (i) 7.0% of the
aggregate gross proceeds in this offering in respect of sales to certain investors and (ii) 2.0% of the aggregate gross proceeds in this offering in respect of sales to certain other investors and to the Company&#146;s Chief Executive Officer. We
have also agreed to reimburse the underwriters at closing for legal and other expenses incurred by them in connection with the offering in an amount not to exceed $125,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 45&nbsp;days after the date of this prospectus supplement, to purchase up to
450,000 additional shares of Class&nbsp;A Common Stock at the public offering price, less the underwriting discount. If the underwriters exercise this option, each underwriter will be obligated, subject to conditions contained in the underwriting
agreement, to purchase a number of additional shares proportionate to the underwriter&#146;s initial amount reflected in the above table. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Underwriters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to the underwriting agreement, we have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments that the underwriters or such other indemnified parties may be
required to make in respect of those liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities by Officers and Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, our directors and certain of our stockholders have agreed, subject to customary exceptions, not to offer, sell, agree
to sell, directly or indirectly, otherwise dispose of or take certain other actions with respect to any shares of Class&nbsp;A Common Stock or any securities convertible into or exchangeable for shares of Class&nbsp;A Common Stock, except for the
shares of Class&nbsp;A Common Stock offered in this offering without the prior written consent of Roth Capital Partners and A.G.P., for a period of 30 days following the closing of this offering. Further, we have agreed, subject to certain
exceptions not to offer, sell, agree to sell, directly or indirectly, otherwise dispose of or take certain other actions with respect to any shares of Class&nbsp;A Common Stock or any securities convertible into or exchangeable for shares of
Class&nbsp;A Common Stock, except for the shares of Class&nbsp;A Common Stock offered in this offering, without the prior written consent of Roth Capital Partners and A.G.P. for a period of 30&nbsp;days after the date of this prospectus supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have also agreed not to enter into any &#147;variable rate transactions,&#148; as defined in the underwriting agreement,
for 30&nbsp;days following the closing of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A Common Stock is quoted on Nasdaq under the symbol &#147;CBUS.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
supplement and the accompanying prospectus may be made available in electronic format on websites or through other online services maintained by the underwriters or by their affiliates. In those cases, prospective investors may view offering terms
online and prospective investors may be allowed to place orders online. Other than this prospectus supplement and the accompanying prospectus in electronic format, the information on the underwriters&#146; websites or our website and any information
contained in any other websites maintained by the underwriters or by us is not part of this prospectus supplement, the accompanying prospectus or the registration statement of which this prospectus supplement and the accompanying prospectus
forms&nbsp;a part, has not been approved and/or endorsed by us or the underwriter in its capacity as underwriter, and should not be relied upon by investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering
transactions and penalty bids in accordance with Regulation&nbsp;M under the Exchange Act: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not
exceed a specified maximum. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Over-allotment involves sales by the underwriters of shares in excess of the number of shares the underwriters
are obligated to purchase, which creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not
greater than the number of shares that they may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any
covered short position by either exercising their over-allotment option and/or purchasing shares in the open market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Syndicate covering transactions involve purchases of the Class&nbsp;A Common Stock in the open market after the
distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the over-allotment option. A naked short position occurs if the underwriters sell more shares than could be covered by the over-allotment option. This position can only
be closed out by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could
adversely affect investors who purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when the
Class&nbsp;A Common Stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market
price of our Class&nbsp;A Common Stock or preventing or retarding a decline in the market price of the Class&nbsp;A Common Stock. As a result, the price of our Class&nbsp;A Common Stock may be higher than the price that might otherwise exist in the
open market. These transactions may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters make any representation or prediction as
to the direction or magnitude of any effect that the transactions described above may have on the price of our shares of Class&nbsp;A Common Stock. In addition, neither we nor the underwriters make any representation that the underwriter will engage
in these transactions or that any transaction, if commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer restrictions outside the United States
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriter that would permit a public offering of the
securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material
or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is not a
disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D
of the Australian Corporations Act. Accordingly, (i)&nbsp;the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act
under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii)&nbsp;this prospectus is made available in Australia only to those persons as set forth in clause (i)&nbsp;above, and (iii)&nbsp;the offeree must be sent a
notice stating in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i)&nbsp;above, and, unless permitted under the Australian Corporations
Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12&nbsp;months after its transfer to the offeree under this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold in
Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the
Securities Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be
made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for
rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal
advisor. Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriter is not required to comply with the disclosure
requirements of <FONT STYLE="white-space:nowrap">NI33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>China
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the
People&#146;s Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to
legal or natural persons other than directly to &#147;qualified domestic institutional investors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area&#151;Belgium, Germany,
Luxembourg and Netherlands </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this document has been prepared on the basis that all offers of securities will be made
pursuant to an exemption under the Directive 2003/71/EC (&#147;Prospectus Directive&#148;), as implemented in Member States of the European Economic Area (each, a &#147;Relevant Member State&#148;), from the requirement to produce a prospectus for
offers of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An offer to the public of securities has not been made, and may not be made, in a Relevant Member State except
pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized
or regulated, whose corporate purpose is solely to invest in securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity that has two or more of (i)&nbsp;an average of at least 250 employees during its last fiscal
year; (ii)&nbsp;a total balance sheet of more than &#128;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii)&nbsp;an annual net turnover of more than &#128;50,000,000 (as shown on its last annual
unconsolidated or consolidated financial statements); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 100 natural or legal persons (other than qualified investors within the meaning of
Article&nbsp;2(1)(e) of the Prospectus Directive) subject to obtaining our prior consent or any underwriter for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, provided that no such
offer of securities shall require us to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>France </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in
France within the meaning of <FONT STYLE="white-space:nowrap">Article&nbsp;L.411-1</FONT> of the French Monetary and Financial Code (Code mon&eacute;taire et financier) and Articles <FONT STYLE="white-space:nowrap">211-1</FONT> et seq. of the
General Regulation of the French Autorit&eacute; des march&eacute;s financiers (&#147;AMF&#148;). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in
France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such offers,
sales and distributions have been and shall only be made in France to (i)&nbsp;qualified investors (investisseurs qualifi&eacute;s) acting for their own account, as defined in and in accordance with Articles <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.411-2-II-2</FONT></FONT></FONT> and <FONT STYLE="white-space:nowrap">D.411-1</FONT> to <FONT STYLE="white-space:nowrap">D.411-3,</FONT> D. <FONT STYLE="white-space:nowrap">744-1,</FONT> <FONT
STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the French Monetary and Financial Code and any implementing regulation and/or (ii)&nbsp;a restricted number of
<FONT STYLE="white-space:nowrap">non-qualified</FONT> investors (cercle restreint d&#146;investisseurs) acting for their own account, as defined in and in accordance with Articles <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">L.411-2-II-2&deg;</FONT></FONT></FONT> and <FONT STYLE="white-space:nowrap">D.411-4,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT
STYLE="white-space:nowrap">D.764-1</FONT> of the French Monetary and Financial Code and any implementing regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to <FONT
STYLE="white-space:nowrap">Article&nbsp;211-3</FONT> of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in
accordance with Articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the French Monetary and Financial Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ireland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with
or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations&nbsp;2005 (the
&#147;Prospectus Regulations&#148;). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i)&nbsp;qualified investors as defined in
Regulation&nbsp;2(l) of the Prospectus Regulations and (ii)&nbsp;fewer than 100 natural or legal persons who are not qualified investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Israel
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA,
nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in
connection with this offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in
Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Italy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of the securities in
the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ&agrave; e la Borsa, &#147;CONSOB&#148; pursuant to the Italian securities legislation and, accordingly, no offering
material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article&nbsp;1.1(t) of Legislative Decree No.&nbsp;58 of 24 February&nbsp;1998
(&#147;Decree No.&nbsp;58&#148;), other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to Italian qualified investors, as defined in Article&nbsp;100 of Decree no. 58 by reference to <FONT
STYLE="white-space:nowrap">Article&nbsp;34-ter</FONT> of CONSOB Regulation no.&nbsp;11971 of 14 May&nbsp;1999 (&#147;Regulation no.&nbsp;1197l&#148;) as amended (&#147;Qualified Investors&#148;); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in other circumstances that are exempt from the rules on public offer pursuant to Article&nbsp;100 of Decree
No.&nbsp;58 and <FONT STYLE="white-space:nowrap">Article&nbsp;34-ter</FONT> of Regulation&nbsp;No. 11971 as amended. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements
where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in
accordance with Legislative Decree No.&nbsp;385 of 1 September&nbsp;1993 (as amended), Decree No.&nbsp;58, CONSOB Regulation&nbsp;No. 16190 of 29 October&nbsp;2007 and any other applicable laws; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus
requirement rules provided under Decree No.&nbsp;58 and the Regulation&nbsp;No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void
and in the liability of the entity transferring the securities for any damages suffered by the investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under Article&nbsp;4, paragraph 1 of the Financial Instruments and Exchange Law of
Japan (Law No.&nbsp;25 of 1948), as amended (the &#147;FIEL&#148;) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with
Article&nbsp;2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified
Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the
execution of an agreement to that effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Zealand </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Class&nbsp;A Common Stock offered hereby have not been offered or sold, and will not be offered or sold, directly or indirectly
in New Zealand and no offering materials or advertisements have been or will be distributed in relation to any offer of shares in New Zealand, in each case other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to persons whose principal business is the investment of money or who, in the course of and for the purposes of
their business, habitually invest money; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to persons who in all the circumstances can properly be regarded as having been selected otherwise than as
members of the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to persons who are each required to pay a minimum subscription price of at least NZ$500,000 for the shares before
the allotment of those shares (disregarding any amounts payable, or paid, out of money lent by the issuer or any associated person of the issuer); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in other circumstances where there is no contravention of the Securities Act 1978 of New Zealand (or any
statutory modification or reenactment of, or statutory substitution for, the Securities Act 1978 of New Zealand). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Portugal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is not being distributed in the context of a public offer of financial securities (oferta p&uacute;blica de valores
mobili&aacute;rios) in Portugal, within the meaning of Article&nbsp;109 of the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The securities have not been offered or sold and will not be offered or sold, directly or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market
Commission (Comiss&#259;o do Mercado de Valores Mobili&aacute;rios) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that
are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are &#147;qualified investors&#148; (as defined in the Portuguese Securities
Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sweden
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory
Authority). Accordingly, this document may not be made available, nor may </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the securities be offered for sale in Sweden, other than under circumstances
that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &#147;qualified
investors&#148; (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Switzerland </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may not be
publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure
standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or
regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss
regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is personal to the recipient only and not for general circulation in Switzerland. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Arab Emirates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this
document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor have we received authorization or licensing from
the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of
an offer or invitation. We may not render services relating to the securities within the United Arab Emirates, including the receipt of applications and/or the allotment or redemption of such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the information
in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act
2000, as amended (&#147;FSMA&#148;)) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to &#147;qualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investors&#148; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any
accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may
its contents be disclosed by recipients to any other person in the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any invitation or inducement to engage in investment
activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United
Kingdom in circumstances in which section 21(1) of FSMA does not apply us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United Kingdom, this document is being distributed only
to, and is directed at, persons (i)&nbsp;who have professional experience in matters relating to investments falling within Article&nbsp;19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order
2005 (&#147;FPO&#148;), (ii) who fall within the categories of persons referred to in Article&nbsp;49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated
(together &#147;relevant persons&#148;). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person
should not act or rely on this document or any of its contents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full-service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their affiliates have provided
in the past to us and our affiliates, and may in the future provide, various commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have
received and may continue to receive customary fees and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business
activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps
and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve and relate to our assets, securities or instruments (directly, as collateral securing other
obligations or otherwise) or persons and entities with relationships with us. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and publish or express
independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long or short positions in such assets, securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_10a"></A>CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS FOR
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations, assumptions and qualifications described herein,
the following is a summary of certain U.S. federal income tax considerations of the purchase, ownership and disposition of shares of Class&nbsp;A Common Stock issued pursuant to this offering (the &#147;Shares&#148;) to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below). Prospective holders of the Shares should consult their tax advisors with respect to the U.S. federal, state, local
<FONT STYLE="white-space:nowrap">and&nbsp;non-U.S.&nbsp;tax</FONT> consequences of the purchase, ownership and disposition of the Shares. This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;), existing U.S. Treasury regulations promulgated thereunder, published administrative pronouncements and rulings of the U.S. Internal Revenue Service (the &#147;IRS&#148;), and judicial decisions, all as in effect as of the date of
this prospectus supplement. These authorities are subject to change and to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion.
There can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and Cibus has not obtained, nor does it intend to obtain, a ruling with respect to the U.S. federal income tax consequences to
a holder of the purchase, ownership or disposition of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion addresses only those Shares that are held as capital
assets within the meaning of Section 1221 of the Code (generally, property held for investment) by holders that acquired such Shares pursuant to this offering. This discussion does not address all the U.S. federal income tax consequences that may be
relevant to particular holders in light of their individual circumstances, nor does it address any alternative minimum, Medicare contribution, estate or gift tax consequences, or any aspects of U.S. state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes). It does not address holders that are subject to special rules, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies or other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt&nbsp;organizations</FONT> or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect to use
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;method</FONT></FONT> of accounting for their securities holdings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold any of the Shares as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion
transaction,&#148; or other risk reduction transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell any of the Shares under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities or arrangements classified as partnerships for U.S. federal income tax purposes or other pass-through
entities (or investors in such entities or arrangements); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies or real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations, passive foreign investment companies or corporations that accumulate earnings to
avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of
the interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or former long-term residents of the United States; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders that acquire the Shares through the exercise of an employee stock option or otherwise as compensation or
through <FONT STYLE="white-space:nowrap">a&nbsp;tax-qualified&nbsp;retirement</FONT> plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder is a partnership
or other pass-through entity (including an entity or arrangement treated as a partnership or other type of pass-through entity for U.S. federal income tax purposes), the U.S. federal income tax treatment of a partner or beneficial owner will
generally depend on the status of such partner or beneficial owner and the entity&#146;s activities. Partnerships, partners and beneficial owners in partnerships or other pass-through entities should consult their tax advisors as to the particular
U.S. federal income tax considerations applicable to the acquisition, ownership and disposition of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;U.S. person&#148; is a beneficial owner of the
Shares, that, for U.S. federal income tax purposes is, or is treated as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual that is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or an entity treated as a corporation, created or organized in or under the laws of the United
States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (1)&nbsp;is subject to (A)&nbsp;the primary supervision of a court within the United States and
(B)&nbsp;the authority of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code) to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S.
Treasury regulations to be treated as a United States person; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate that is subject to U.S. federal income tax on its income regardless of its source.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the <FONT STYLE="white-space:nowrap">term&nbsp;&#147;Non-U.S.&nbsp;Holder&#148;</FONT> means a
beneficial owner, other than an entity treated as a partnership for U.S. federal income tax purposes, of the Shares that is, for U.S. federal income tax purposes, not a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>PROSPECTIVE INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR FEDERAL, STATE, LOCAL
<FONT STYLE="white-space:nowrap">AND&nbsp;NON-U.S.&nbsp;TAX</FONT> CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF THE SHARES. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions on the Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus
does not anticipate declaring or paying any cash dividends to holders of Cibus&#146;s Class&nbsp;A Common Stock in the foreseeable future. However, distributions of cash or other property (other than certain distributions of stock) on the Shares
will constitute dividends to&nbsp;the extent paid out of Cibus&#146;s current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. Distributions in excess of Cibus&#146;s current and accumulated earnings and
profits will constitute a return of capital and first be applied against and reduce <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> adjusted tax basis in its&nbsp;Shares, but not below zero. Any excess will be subject to
the treatment as described below under &#147;&#151;Gain on the Sale, Exchange or Other Taxable Disposition of the Shares.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends
paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are not effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business in the United States generally will be
subject to withholding tax at a <FONT STYLE="white-space:nowrap">30-percent</FONT> rate or a reduced rate specified by an applicable income tax treaty. In order to obtain a reduced rate of withholding, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide Cibus or Cibus&#146;s paying agent with a properly executed applicable IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or appropriate successor form), as applicable, certifying under penalties of perjury that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not a U.S.
person and is eligible for the benefits under the applicable income tax treaty. These forms may need to be periodically updated. If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds the Shares through a financial institution or other
intermediary, the Non-U.S. Holder generally will be required to provide the appropriate documentation to the financial institution or other intermediary. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder eligible for a reduced rate of U.S.
withholding tax pursuant to an income tax treaty who fails to timely provide an IRS Form W-8BEN or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or appropriate successor form), as applicable, may obtain a
refund of any excess amounts withheld by timely filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If dividends paid to a Non-U.S. Holder are
effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base maintained by the Non-U.S.
Holder in the United States), the Non-U.S. Holder will generally be taxed on the dividends in the same manner as a U.S. person. In this case, the Non-U.S. Holder will be exempt from the withholding tax discussed in the preceding paragraph, although
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide a properly executed IRS Form W-8ECI (or appropriate successor form) in order to claim an exemption from withholding. Such effectively connected dividends,
although not subject to U.S. federal withholding tax, are subject to U.S. federal income tax on a net income basis at the regular graduated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. federal income tax rates generally applicable to a U.S. person. Dividends received by a corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with
such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, attributable to a permanent establishment or fixed base maintained by the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States) may be subject to an additional branch profits tax at a 30-percent rate (or such lower rate as may be specified by an applicable income tax treaty). Non-U.S. Holders should
consult their tax advisors with respect to other U.S. tax consequences of the acquisition, ownership and disposition of the Shares, including the possible imposition of the branch profits tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain on the Sale, Exchange or Other Taxable Disposition of the Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below under &#147;&#151;Information Reporting and Backup Withholding&#148; and &#147;&#151;FATCA,&#148; a Non-U.S.
Holder generally will not be subject to U.S. federal income or withholding tax on gain realized on a sale, exchange or other taxable disposition of the Shares unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct
of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United
States), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> is a nonresident alien individual present
in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus is or has been a &#147;United States real property holding corporation,&#148; as defined in the Code, at
any time within the five-year period ending on the date of disposition or <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> holding period, whichever period is shorter, and
<FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> is not eligible for an exemption under an applicable income tax treaty. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that it is not, and does not anticipate becoming, a United States real property holding corporation.<B> </B>Even if Cibus is or
has been a United States real property holding corporation during the specified testing period, as long as Cibus&#146;s Class A Common Stock is regularly traded on an established securities market (such as the Nasdaq Capital Market) at any time
during the calendar year in which the disposition occurs, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on the disposition of the Shares if the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder does not own or has not owned (actually or constructively) more than 5 percent of Cibus&#146;s Class A Common Stock at any time during the shorter of the two periods mentioned above. Non-U.S.
Holders are urged to consult their tax advisors regarding the application of this regularly traded exception, including the effect of holding warrants or other rights to acquire Class A Common Stock on the calculation of the <FONT
STYLE="white-space:nowrap">5-percent</FONT> threshold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, although a 15% withholding tax generally applies to gross proceeds
from the sale, exchange or other taxable disposition of the stock of a United States real property holding company, such 15% withholding tax generally will not apply to the disposition of the Shares so long as Cibus&#146;s Class&nbsp;A Common Stock
is regularly traded on an established securities market. However, the exception described in the previous sentence may not apply to certain dispositions of the Shares if <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> exceeds
the <FONT STYLE="white-space:nowrap">5-percent</FONT> threshold mentioned above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder recognizes gain on a sale, exchange or other taxable disposition of the Shares that is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business in the United States (and if
required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States), the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally be subject to U.S. federal income tax at the regular graduated U.S. federal income tax rates generally applicable to a U.S. person. If the Non-U.S. Holder is a corporation, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject to the branch profits tax at a <FONT STYLE="white-space:nowrap">30-percent</FONT> rate or such lower rate as may be specified by an applicable income tax treaty. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors with respect to other U.S. tax consequences of the acquisition, ownership and disposition of the Shares, including the possible imposition of the branch profits
tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends on the Shares. Copies of the information returns
reporting those dividends and withholding may also be made available to the tax authorities in the country in which <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> is a resident under the provisions of an applicable income tax
treaty or agreement. Unless <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> complies with certification procedures to establish that <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> is not a U.S. person,
information returns may also be filed with the IRS in connection with the proceeds from a sale, exchange or other taxable disposition of the Shares to or through the U.S. office (and, in certain cases, the foreign office) of a broker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be subject to backup withholding (currently at a rate of 24 percent) on payments
on the Shares or on the proceeds from a sale, exchange or other taxable disposition of the Shares unless the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder complies with certification procedures to establish that the Non-U.S. Holder is not
a U.S. person or otherwise establishes an exemption. Compliance with the certification procedures required to claim a reduced rate of withholding under a treaty (including properly certifying non-U.S. status on an IRS Form W-8BEN, IRS Form <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate version of IRS Form W-8 (or appropriate successor form)) generally will satisfy the certification requirements necessary to avoid backup
withholding as well. Notwithstanding the foregoing, U.S. federal backup withholding may apply if the payor has actual knowledge, or reason to know, that a holder is a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld from a payment to a Non-U.S. Holder under the backup withholding rules
generally will be allowed as a credit against such Non-U.S. Holder&#146;s U.S. federal income tax liability and may entitle such Non-U.S. Holder to a refund, provided the required information is furnished to the IRS in a timely manner. Non-U.S.
Holders are urged to consult their tax advisors regarding the application of backup withholding and the availability of and procedure for obtaining an exemption from backup withholding in their particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FATCA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of the Code commonly
referred to as &#147;FATCA&#148; generally require withholding of 30&nbsp;percent on payments of dividends on the Shares, as well as payments of gross proceeds of dispositions of the Shares, to a &#147;foreign financial institution&#148; (which is
broadly defined for this purpose and in general includes investment vehicles) and certain <FONT STYLE="white-space:nowrap">other&nbsp;non-U.S.&nbsp;entities</FONT> unless various U.S. information reporting and due diligence requirements (generally
relating to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied or an exemption applies. However, the IRS has issued proposed U.S. Treasury regulations that eliminate FATCA withholding on payments of gross
proceeds (but not on payments of dividends). Pursuant to the preamble to the proposed U.S. Treasury regulations, any applicable withholding agent may (but is not required to) rely on this proposed change to FATCA withholding until final U.S.
Treasury regulations are issued or the proposed U.S. Treasury regulations are withdrawn. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. If FATCA withholding is imposed, a
beneficial owner that is not a foreign financial institution generally may obtain a refund of any amounts withheld by filing a U.S. federal income tax return (which may entail significant administrative
<FONT STYLE="white-space:nowrap">burden).&nbsp;Non-U.S.&nbsp;Holders</FONT> should consult their tax advisors regarding the effects of FATCA on their investments in the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus will not pay any additional <FONT STYLE="white-space:nowrap">amounts&nbsp;to&nbsp;Non-U.S.&nbsp;Holders</FONT> with respect to any
amounts withheld, including pursuant to FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE PRECEDING DISCUSSION OF U.S. FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION
ONLY. IT IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND <FONT STYLE="white-space:nowrap">LOCAL&nbsp;AND&nbsp;NON-U.S.&nbsp;TAX&nbsp;CONSEQUENCES</FONT> OF PURCHASING,
OWNING AND DISPOSING OF THE SHARES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jones Day, New York, New York, will pass upon the validity of the issuance of the securities offered hereby. Certain legal matters relating to
the offering will be passed upon for the underwriters by Sullivan&nbsp;&amp; Worcester LLP, New York, New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Cibus, Inc. as of and for the year ended December&nbsp;31, 2022 appearing in Cibus, Inc.&#146;s
Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2023, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which
contains an explanatory paragraph describing conditions that raise substantial doubt about Cibus, Inc.&#146;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), included therein, and incorporated
herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Cibus, Inc. (the Company) as of December&nbsp;31, 2023, and for the year then ended, incorporated by
reference in this prospectus supplement, have been so incorporated in reliance upon the report of BDO USA, P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The report
on the consolidated financial statements contains an explanatory paragraph regarding the Company&#146;s ability to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_13"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect to
the shares of Class&nbsp;A Common Stock offered hereby. This prospectus supplement and the accompanying prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement or the exhibits filed with the registration statement. For further information about us and the Class&nbsp;A Common Stock offered hereby, we refer you to the registration statement and the exhibits filed with the registration statement.
Statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such
statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, are required to file
periodic reports, proxy statements and other information with the SEC. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&#146;s website at
http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make available free of charge, on or through the investor relations section of our website, Annual Reports on Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnished it to, the SEC. The information found on our website, www.cibus.com, other than as specifically
incorporated by reference in this prospectus supplement, is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom885907_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information that we file with them. Incorporation by reference allows us to disclose
important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus supplement and the accompanying prospectus, and information that we file later with the SEC
will automatically update and supersede this information. We filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, with the SEC with respect to the securities being offered pursuant to this
prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus omit certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration
statement, including the exhibits, for further information about us and the securities being offered pursuant to this prospectus supplement and the accompanying prospectus. Statements in this prospectus supplement and the accompanying prospectus
regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any part of the
registration statement, including the documents incorporated by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC listed above in &#147;Where You Can Find Additional Information.&#148; The
documents we are incorporating by reference are (other than those documents or the portions of those documents not deemed to be filed): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000162828024012546/cbus-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2023, filed with the SEC on March&nbsp;21, 2024, including information specifically incorporated by reference into the Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> from our <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000162828024016939/cbus-20240419.htm">definitive proxy statement</A> for the 2024 Annual Meeting of
Stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended March&nbsp;31,
2024 and June&nbsp;
30, 2024, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000162828024022280/cbus-20240331.htm">May 9, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000162828024036185/cbus-20240630.htm">August&nbsp;8,
 2024</A>, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001705843/000119312524000212/d118469d8k.htm">January&nbsp;2,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001705843/000162828024000957/cbus-20240109.htm">January&nbsp;
9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001705843/000119312524063755/d808151d8k.htm">March&nbsp;
8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001705843/000162828024012559/cbus-20240321.htm">March&nbsp;
21, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001705843/000162828024026561/cbus-20240530.htm">June&nbsp;
4, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001705843/000119312524160319/d850268d8k.htm">June&nbsp;
13, 2024</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001705843/000119312524204017/d870033d8k.htm">August&nbsp;21, 2024</A> (in each case, excluding any information furnished and not filed with the
SEC); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our Class&nbsp;
A Common Stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312517231512/d433769d8a12b.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed on July&nbsp;20, 2017, as the
description therein has been updated and superseded by the description of capital stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523178748/d450252dex991.htm">Exhibit 99.1</A> to our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on June&nbsp;29, 2023, including any amendments or reports filed for the purpose of updating the description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus supplement is a part and prior to effectiveness of such registration statement, until we file a
post-effective amendment that indicates the termination of the offering of the shares of Class&nbsp;A Common Stock made by this prospectus supplement and will become a part of this prospectus supplement from the date that such documents are filed
with the SEC. Information in such future filings updates and supplements the information provided in this prospectus supplement. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any
document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon request, we will provide, without charge, to each person, including any beneficial
owner, to whom a copy of this prospectus supplement and the accompanying prospectus is delivered a copy of the documents incorporated by reference into this prospectus supplement. You may request a copy of these filings, and any exhibits we have
specifically incorporated by reference as an exhibit in this prospectus supplement and the accompanying prospectus, at no cost by writing or telephoning us at the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cibus, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6455 Nancy Ridge
Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(858) <FONT STYLE="white-space:nowrap">450-0008</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the SEC&#146;s website at www.sec.gov or on the &#147;Investors&#148; page of our
website at www.cibus.com. Other than such documents, information contained on our website is not incorporated by reference into this prospectus supplement and the accompanying prospectus, and you should not consider any information on, or that can
be accessed from, our website as part of this prospectus supplement or the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the
accompanying prospectus is part of a registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the exhibits carefully for provisions that may be important to you. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g885907g72e66.jpg" ALT="LOGO" STYLE="width:2.5625in;height:0.625in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Subscription
Rights </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
relates to the offer and sale by us of up to an aggregate $200,000,000 of the securities identified above (the &#147;securities&#148;) of Cibus, Inc. (the &#147;Company,&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities offered hereby, including the Company&#146;s Class&nbsp;A Common
Stock, par value $0.0001 per share (the &#147;Class&nbsp;A Common Stock&#148;), and the general manner in which we will offer such securities. More specific terms of any securities that we offer may be provided in a prospectus supplement that
describes, among other things, the specific amounts and prices of the securities being offered and the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. In addition, the Company
may supplement, update or change any of the information contained in this prospectus by incorporating information by reference into this prospectus. References in this prospectus to the Company also refer to Calyxt, Inc. to the extent prior to the
closing of the Company&#146;s merger with Cibus Global, LLC (&#147;Cibus Global&#148;) on May&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell these
securities separately or in combination from time to time in amounts, at prices and on terms to be determined by market conditions and other factors at the time of our offerings, including at prevailing market prices or at prices negotiated with
buyers. We may offer and sell these securities through agents, through underwriters or dealers or directly to one or more purchasers, including existing stockholders. This prospectus provides you with a general description of these securities and
the general manner in which we will offer the securities. Each time securities are offered, we will provide a prospectus supplement that will contain specific information about the terms of that offering. For example, any specific allocation of the
net proceeds of an offering of securities to a specific purpose and any commissions or discounts payable to agents, dealers or underwriters will be determined at the time of the offering and will be described in any applicable prospectus supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A Common Stock is traded on the Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;CBUS&#148;. The closing
price for our Class&nbsp;A Common Stock on October 24,&nbsp;2023, was $13.82 per share, as reported on Nasdaq. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves risks. See &#147;<A HREF="#tx885907_4">Risk Factors</A>&#148; beginning on page&nbsp;5 of this prospectus and under similar headings in the applicable prospectus supplement and the documents incorporated by reference for a
discussion of facts you should carefully consider before investing in the securities. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of the securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is October 27,&nbsp;2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TABLE OF CONTENTS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_3">INFORMATION ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_8">DESCRIPTION OF DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_10">DESCRIPTION OF SUBSCRIPTION RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_11">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885907_15">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>We have not authorized anyone to provide any information or to make any representations other than those contained or incorporated by
reference in this prospectus, any accompanying prospectus supplement or any free writing prospectus we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give
you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. The information contained or incorporated by reference in this prospectus is current only as
of its date. Cibus&#146; business, financial condition, results of operations and prospects may have changed since such date</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;) using a &#147;shelf&#148; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus from time to time and in one or more
offerings up to a total dollar amount of $200,000,000. This prospectus generally describes Cibus, Inc. and our securities, including our Class&nbsp;A Common Stock. We may use the shelf registration statement to sell the listed securities from time
to time through any means described in the section entitled &#147;Plan of Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More specific terms of any securities we
offer may be provided in a prospectus supplement that describes, among other things, the specific amounts and prices of the securities being offered, any specific allocation of the net proceeds of an offering of securities to a specific purpose and
other terms of the offering. The prospectus supplement may also add, update or change information included in this prospectus. You should read both this prospectus and any applicable prospectus supplement, together with additional information
described below under the captions &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No offer of the securities will be made in any jurisdiction where the offer is not permitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The information in this prospectus contains or incorporates by reference information that includes or is based upon &#147;forward-looking
statements&#148; within the meaning of the federal securities laws, including Section&nbsp;27A of the Securities Act of 1933 and the rules and regulations promulgated thereunder (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities
Exchange Act of 1934 and the rules and regulations promulgated thereunder (the &#147;Exchange Act&#148;). Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of
activity, performance or achievements. In some cases, you can identify these statements by forward-looking words such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148;
&#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue,&#148; the negative of these terms and other comparable terminology. These forward-looking statements, which are
subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our
current expectations and projections about future events. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the
results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including, without limitation, factors relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the possible failure to realize certain anticipated benefits of the transactions
contemplated by the Company&#146;s merger with Cibus Global that closed on May&nbsp;31, 2023 (the &#147;Merger Transactions&#148;), including with respect to future financial and operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of the completion of the Merger Transactions on our business relationships, operating results and
business generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any litigation related to the Merger Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitive responses to the Merger Transactions and changes in expected or existing competition;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges to our intellectual property protection and unexpected costs associated with defending our
intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased or unanticipated time and resources required for our platform or trait product development efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties in connection with our development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively license our productivity traits and sustainable ingredient products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recognition of value in our products by farmers, and the ability of farmers and processors to work
effectively with crops containing our traits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to produce high-quality plants and seeds cost effectively on a large scale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need for additional funding to finance our activities and challenges in obtaining additional capital on
acceptable terms, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our dependence on distributions from Cibus Global to pay taxes and cover our corporate and overhead expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments that disfavor or impose significant burdens on gene-editing processes or products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve commercial success; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commodity prices and other market risks facing the agricultural sector; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological developments that could render our technologies obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising
interest rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity
challenges on the Company&#146;s ability to execute on its business plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that we will not be able to execute a financing transaction in the near term or at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount reductions and other cost reduction measures may result in operational and strategic challenges.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">While the list of factors presented here is considered representative, no such list should be considered to be a
complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those
anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on our
consolidated financial condition, results of operations or liquidity. Therefore, you should not rely on any of these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Should one or more of the risks or uncertainties described in this prospectus occur, or should underlying assumptions prove incorrect, our
actual results and plans could differ materially from those expressed in any forward-looking statements. All forward-looking statements, expressed or implied, included in this prospectus are expressly qualified in their entirety by this cautionary
statement. This cautionary statement should also be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. Any forward-looking statement made by us in this
prospectus is based only on information currently available to us and speaks only as of the date hereof. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements after the date of this prospectus,
whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_3"></A>INFORMATION ABOUT THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are a leading
agricultural technology company in the plant seed industry. We are not a seed company. We are a gene editing-based technology company whose business is to develop and license plant traits to seed companies in exchange for royalties. Our target trait
market is productivity traits that improve yields, lower input (such as chemicals) costs, and increase the sustainability and profitability of farming. We have a pipeline of six productivity traits, four of which are applicable to multiple crops.
Three of our traits are developed, field validated, have been edited into the elite lines of seed company partners and have started being transferred to these partners for pre-commercialization testing. These traits are pod shatter resistance (PSR)
in Canola and two herbicide resistance traits: HT1 and HT3; in Rice. In addition, we have two advanced traits (<I>i.e.,</I> where the editing process is underway with known edit targets) for <I>Sclerotinia Resistance</I> and another novel herbicide
resistance trait: HT2. Cibus&#146; work in nitrogen use efficiency is in its early stages. Our primary commercial objective is advancing our three developed traits: PSR, HT1 and HT3 into customer commercial lines in Canola, WOSR and Rice. Because of
the strategic realignment in October 2023, certain development timelines not linked to the initial and advanced traits, such as those associated with the development of our corn and wheat platform, are expected to be extended beyond our initial
anticipated targets. In addition, we are developing, solely through partner-funded projects, certain output traits to meet the functional needs of the new sustainable ingredients industry to replace current ingredients that are plastics or fossil
fuel based or that cause deforestation or raise other sustainability challenges. Our Class&nbsp;A Common Stock trades on Nasdaq under the symbol &#147;CBUS.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> Corporate Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are a holding company with substantially all of our assets and operations conducted through Cibus Global and its subsidiaries. Our sole
material asset consists of our interest in Cibus Global. We are the sole managing member of Cibus Global and are responsible for all operational, management and administrative decisions relating to Cibus Global&#146;s business and consolidate the
financial results of Cibus Global and its subsidiaries. Owners of Cibus Global&#146;s Common Units (&#147;Cibus Global Common Units&#148;) other than us own a corresponding number of shares of our Class&nbsp;B common stock, par value $0.0001 per
share (the &#147;Class&nbsp;B Common Stock,&#148; and together with the Class&nbsp;A Common Stock, the &#147;Shares&#148;), which have voting (but no economic) rights with respect to Cibus, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our principal
executive offices are located at 6455 Nancy Ridge Drive, San Diego, CA 92121 and our telephone number is (858) <FONT STYLE="white-space:nowrap">450-0008.</FONT> Cibus&#146; filings with the SEC are posted on its corporate website at
<I>www.cibus.com</I>. The information found on our website is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">An investment in our securities involves a high degree of risk. You should carefully consider those risk factors described in Exhibit 99.3 to
our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on June&nbsp;1, 2023, under the heading &#147;Risk Factors&#148; in any subsequently filed Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and
Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than, in each case, information furnished rather than filed), which are incorporated by reference herein, and those risk factors that may be included in any applicable
prospectus supplement, together with all of the other information included in this prospectus, any prospectus supplement and the documents we incorporate by reference, in evaluating an investment in our securities. Our business, prospects, financial
condition or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that we currently consider immaterial. The trading price of our Class&nbsp;A Common Stock could decline due to any of these
risks, and, as a result, you may lose all or part of your investment. Before deciding whether to invest in our securities, you should also refer to the other information contained in or incorporated by reference into this prospectus, including the
section entitled &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in any applicable prospectus supplement, we intend to use the net proceeds we receive from the sale of securities
for general corporate purposes. General corporate purposes may include research and development costs, the acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of traits or technologies, repayment and refinancing of debt, working
capital and capital expenditures. As a result, management will retain broad discretion over the allocation of net proceeds of any offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The specific allocation of the net proceeds of an offering of securities to a specific purpose if any, will be determined at the time of the
offering and will be described in any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may use one or more of the following methods when selling securities under this prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">underwritten transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange distributions and/or secondary distributions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such stock at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades (which may involve crosses) in which the broker-dealer so engaged will attempt to sell the
securities as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its own account;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales and delivery of shares of our Class&nbsp;A Common Stock to close out short positions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales by broker-dealers of shares of our Class&nbsp;A Common Stock that are loaned or pledged to such
broker-dealers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT>
offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as dividends or through a distribution of subscription rights to our existing security holders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may prepare prospectus supplements that will disclose the terms of the offering, including the name or names of any underwriters, dealers
or agents, the purchase price of the securities, any underwriting discounts and other items constituting compensation to underwriters, dealers or agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may fix a price or prices of our securities at: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market prices prevailing at the time of any sale under this registration statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prices related to market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may change the price of the securities offered from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We may sell securities through brokers, dealers, agents or underwriters, who may act on a best efforts basis for a specified period of
appointment or on a firm commitment basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If we use underwriters in an offering, we will execute an underwriting agreement with such
underwriters and will specify the name of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement. If we use an
underwriting syndicate, the managing underwriter(s) will be specified on the cover of the prospectus supplement. If we use underwriters for a sale of securities, the underwriters will acquire the securities for their own accounts. The underwriters
may resell the securities from time to time in one or more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may be changed from time to time. Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions precedent and the
underwriters will be obligated to purchase all of the offered securities if any are purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If dealers are used in an offering, we may
sell the securities to the dealers as principals. The dealers then may resell the securities to the public at varying prices which they determine at the time of resale. The names of the dealers and the terms of the transaction will be specified in a
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If agents are used in an offering, the names of the agents and the terms of the agency will be specified in a
prospectus supplement. Unless otherwise indicated in a prospectus supplement, the agents will act on a best-efforts basis for the period of their appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Dealers and agents named in a prospectus supplement may be underwriters as defined in the Securities Act and any discounts or commissions they
receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act. We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will
describe their compensation. We may enter into agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers or agents and their associates may engage in other transactions with and perform other services for us in the ordinary
course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If so indicated in a prospectus supplement, we will authorize underwriters or other persons acting as our agents to
solicit offers by institutional investors to purchase securities pursuant to contracts providing for payment and delivery on a future date. We may enter contracts with commercial and savings banks, insurance companies, pension funds, investment
companies, educational and charitable institutions and other institutional investors. The obligations of any institutional investor will be subject to the condition that its purchase of the offered securities will not be illegal at the time of
delivery. The underwriters and other agents will not be responsible for the validity or performance of contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, we may
enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those
derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to
settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be
an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities
short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain
or otherwise affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position
for their own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market.
Finally, in any offering of the securities through a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate
repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent
market levels. Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
place and time of delivery for securities will be set forth in the accompanying prospectus supplement. Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act, trades in the secondary market generally are required to settle in
two business days, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for securities may be more than two scheduled business days after the trade date for
your securities. Accordingly, in such a case, if a purchaser wishes to trade securities on any date prior to the second business day before the original issue date for such securities, the purchaser will be required, by virtue of the fact that such
securities initially are expected to settle in more than two scheduled business days after the trade date for such securities, to make alternative settlement arrangements to prevent a failed settlement. To comply with applicable state securities
laws, the securities offered by this prospectus will be sold, if necessary, in such jurisdictions only through registered or licensed brokers or dealers. In addition, securities may not be sold in some states absent registration or pursuant to an
exemption from applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities and may have no established trading
market. The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will be described in any
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To the extent required, this prospectus may be amended or supplemented from time to time to describe a
specific plan of distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following summary of certain material provisions of our capital stock does not purport to be complete and is subject to and qualified by
reference to our second amended and restated certificate of incorporation (our &#147;Amended and Restated Charter&#148;) and our amended and restated bylaws (our &#147;Amended Bylaws&#148;). The summary below is also qualified by reference to the
provisions of the Delaware General Corporation Law (the &#147;DGCL&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our total number of authorized shares of capital stock consists of (i) 210,000,000 shares of Class&nbsp;A Common Stock, (ii) 90,000,000 shares
of Class&nbsp;B Common Stock, and (iii) 10,000,000 shares of preferred stock, par value of $0.0001 per share (&#147;Preferred Stock&#148;). As of the date of this prospectus, we had outstanding 17,608,959 shares of Class&nbsp;A Common Stock,
4,642,636 shares of Class&nbsp;B Common Stock and no shares of Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Holders of shares of Class&nbsp;A Common Stock are entitled to one vote for each share held of record on all matters on
which stockholders are entitled to vote generally, except that holders of shares of Class&nbsp;A Common Stock have no voting power with respect to, and are not be entitled to vote on, any amendment to the Amended and Restated Charter (including any
certificate of designations relating to any series of Preferred Stock) that relates solely to the terms of any outstanding Preferred Stock if the holders of such Preferred Stock are entitled to vote as a separate class thereon under the Amended and
Restated Charter or under the DGCL. The holders of Class&nbsp;A Common Stock do not have cumulative voting rights in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Holders of outstanding shares of Class&nbsp;A Common Stock are entitled to vote separately upon any amendment to the Amended and Restated
Charter (including by merger, consolidation, conversion, reorganization or similar event) that would alter or change the powers, preferences or special rights of Class&nbsp;A Common Stock in a manner that is materially and disproportionately adverse
as compared to the Class&nbsp;B Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights</I>. Holders of shares of Class&nbsp;A Common Stock are entitled to
receive dividends when, as and if declared by our board of directors (our &#147;Board&#148;) out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the
payment of dividends imposed by the terms of any outstanding Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights</I>. Upon its liquidation,
dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of Preferred Stock having liquidation preferences, if any, the holders of shares of Class&nbsp;A Common Stock will be entitled to
receive pro rata the remaining assets available for distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All outstanding shares of Class&nbsp;A Common Stock are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> The Class&nbsp;A Common Stock is not subject to further calls or assessments by us. Holders of shares of Class&nbsp;A Common Stock do not have preemptive, subscription or redemption rights. There is
no redemption or sinking fund provisions applicable to the Class&nbsp;A Common Stock. The rights powers, preferences and privileges of Class&nbsp;A Common Stock are subject to those of the holders of any shares of Class&nbsp;B Common Stock and
Preferred Stock or any other series or class of stock we may authorize and issue in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;B Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Holders of shares of Class&nbsp;B Common Stock are entitled to one vote for each share held of record on all matters on
which stockholders are entitled to vote generally, except that holders of shares of Class&nbsp;B Common Stock have no voting power with respect to, and are not entitled to vote on, any amendment to the Amended and Restated Charter (including any
certificate of designations relating to any series of Preferred Stock) that relates solely to the terms of any outstanding Preferred Stock if the holders of such Preferred Stock are entitled to vote as a separate class thereon under the Amended and
Restated Charter or under the DGCL. The holders of Class&nbsp;B Common Stock do not have cumulative voting rights in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Holders of outstanding shares of Class&nbsp;B Common Stock are entitled to vote separately upon any amendment to the Amended and Restated
Charter (including by merger, consolidation, conversion, reorganization or similar event) that would alter or change the powers, preferences or special rights of Class&nbsp;B Common Stock in a manner that is materially and disproportionately adverse
as compared to the Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Holders of outstanding shares of Class&nbsp;B Common Stock are entitled to vote separately
upon any (A)&nbsp;merger, consolidation, conversion, reorganization or similar event in connection with any transaction or series of transactions intended to result in the Company no longer being structured as an umbrella partnership C corporation
(an <FONT STYLE="white-space:nowrap">&#147;Up-C</FONT> Reorganization Transaction&#148;) or (B)&nbsp;amendment to the Amended and Restated Charter (including by merger, consolidation, conversion, reorganization or similar event) to effect an <FONT
STYLE="white-space:nowrap">Up-C</FONT> Reorganization Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Holders of the Shares vote together as a single class on all matters
(or, if any holders of Preferred Stock are entitled to vote together with the holders of the Shares, as a single class with the holders of Preferred Stock) except as otherwise required in the Amended and Restated Charter or by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights</I>. Holders of Class&nbsp;B Common Stock do not have any right to receive dividends. In no event will any dividend be
declared or made on any Shares unless (1)&nbsp;a corresponding dividend for all other Shares not so adjusted at the time outstanding is made in the same proportion and the same manner and (2)&nbsp;the dividend has been reflected in the same
economically equivalent manner on all Shares. Dividends with respect to Shares may only be paid with shares of stock of the same class of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights</I>. Holders of Class&nbsp;B Common Stock do not have any right to receive a distribution upon a liquidation,
dissolution or winding up of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Retirement of Shares</I>. No holder of Class&nbsp;B Common Stock may transfer shares of
Class&nbsp;B Common Stock to any person unless such holder transfers a corresponding number of Cibus Global Common Units to the same person in accordance with the provisions of Cibus Global&#146;s operating agreement (the &#147;Cibus Global Amended
Operating Agreement&#148;). If any outstanding share of Class&nbsp;B Common Stock ceases to be held by a holder of the corresponding Cibus Global Common Unit, such share shall automatically and without further action on the part of the Company or
any holder of Class&nbsp;B Common Stock be transferred to the Company for no consideration and retired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Issuance of Cibus Global
Common Units</I>. To the extent Cibus Global Common Units are issued pursuant to the Cibus Global Amended Operating Agreement to anyone other than the Company or a wholly owned subsidiary of Cibus, Inc., an equivalent number of shares of
Class&nbsp;B Common Stock (subject to adjustment) will be issued at par to the same person to which such Cibus Global Common Units are issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No shares of Preferred Stock are issued or outstanding as of the date of this prospectus. The Amended and Restated Charter authorizes our Board
to establish one or more series of Preferred Stock. Our Board will be able to determine, with respect to any series of Preferred Stock, the powers (including voting powers), and the designations, preferences and relative, participating, optional or
other special rights, and any qualifications, limitations or restrictions thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The DGCL permits a corporation to declare and pay dividends out of &#147;surplus&#148; or, if there is no &#147;surplus,&#148; out of its net
profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. &#147;Surplus&#148; is defined as the excess of the net assets of the corporation over the amount determined to be the capital of the corporation by its
board of directors. The capital of the corporation is typically calculated to be (and cannot be less than) the aggregate par value of all issued shares of capital stock. Net assets equals the fair value of the total assets minus total liabilities.
The DGCL also provides that dividends may not be paid out of net profits if, after the payment of the dividend, remaining capital would be less than the capital represented by the outstanding stock of all classes having a preference upon the
distribution of assets. Declaration and payment of any dividend will be subject to the discretion of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have no current plans
to pay dividends on our Class&nbsp;A Common Stock. Any decision to declare and pay dividends in the future will be made at the sole discretion of our Board and will depend on, among other things, our results of operations, cash requirements,
financial condition, contractual restrictions and other factors that our Board may deem relevant. Because we are a holding company and will have no direct operations, we will only be able to pay dividends from funds we receive from our subsidiaries.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Stockholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
Amended Bylaws provide that annual stockholder meetings will be held at a date, time and place, if any, as may be designated by our Board or, in the absence of a designation by our Board, by the chair, the chief executive officer or the secretary.
To the extent permitted under applicable law, we may conduct meetings by remote communications, including by webcast. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of the
Amended and Restated Charter, the Amended Bylaws and Certain Provisions of Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Amended and Restated Charter, the Amended
Bylaws and certain provisions of the DGCL contain provisions, which are summarized in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of our Board. These provisions are intended to
avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control and enhance the ability of our Board to maximize stockholder value in connection with any unsolicited offer to acquire the Company. However, these
provisions may have an anti-takeover effect and may delay, deter or prevent a merger or acquisition of the Company by means of a tender offer, a proxy contest or other takeover attempt that a stockholder might consider in its best interest,
including those attempts that might result in a premium over the prevailing market price for the Shares held by stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized but Unissued
Capital Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Delaware law does not require stockholder approval for any issuance of shares that are authorized and available for
issuance. However, the listing requirements of Nasdaq, which apply so long as our Class&nbsp;A Common Stock remains listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power of
our capital stock or then outstanding number of shares of Class&nbsp;A Common Stock. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate
acquisitions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our Board will be authorized to generally issue shares of one or more series of Preferred
Stock on terms calculated to discourage, delay or prevent a change of control the Company or the removal of our management. Moreover, our authorized but unissued shares of Preferred Stock will be available for future issuances in one or more series
without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, to facilitate acquisitions and employee benefit plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">One of the effects of the existence of authorized and unissued and unreserved Class&nbsp;A Common Stock or Preferred Stock may be to enable
our Board to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control the Company by means of a merger, tender offer, proxy contest or otherwise, and thereby
protect the continuity of our management and possibly deprive our stockholders of opportunities to sell their shares of Class&nbsp;A Common Stock at prices higher than prevailing market prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vacancies and Newly Created Directorships </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Amended and Restated Charter and the Amended Bylaws provide that any vacancies on our Board, and any newly created directorships, will be
filled only by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, and any director so chosen will hold office until the earlier expiration of the term of office of the director whom he or she
has replaced or his or her successor shall be duly elected and qualified or until such director&#146;s earlier death, disqualification, resignation or removal. No decrease in the number of directors shall shorten the term of any director then in
office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Cumulative Voting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Under
Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. The Amended and Restated Charter does not authorize cumulative voting. Therefore, stockholders holding a
majority in voting power of our stock entitled to vote generally in the election of directors will be able to elect all directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Stockholder
Meetings </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Amended and Restated Charter and the Amended Bylaws provide that special meetings of stockholders may be called only by
the chair of our Board, our chief executive officer or at the direction of our Board pursuant to a written resolution adopted by a majority of the total number of directors that we would have if there were no vacancies. Any business transacted at a
special meeting of stockholders will be limited to matters set forth in the notice of the special meeting. These provisions may have the effect of deterring, delaying or discouraging hostile takeovers, or changes in control or our management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Nominations and Stockholder Proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Amended Bylaws establish advance notice procedures with respect to stockholder nominations for the election as directors. In order for any
matter to be &#147;properly brought&#148; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder&#146;s notice must be received at our
principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. The Amended Bylaws also specify requirements as to the form and content of a
stockholder&#146;s notice. The Amended Bylaws allow the chair of the meeting at a meeting of the stockholders to adopt rules and regulations for the conduct of meetings which may have the effect of precluding the conduct of certain business at a
meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to
influence or obtain control of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Action by Written Consent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken
without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less than the minimum number of votes that would be
necessary to authorize or take such action at a meeting at which all shares of stock entitled to vote thereon were present and voted, unless the certificate of incorporation provides otherwise. Our Amended and Restated Charter precludes stockholder
action by written consent; provided, however, that any action required or permitted to be taken by the holders of Class&nbsp;B Common Stock, voting separately as a class, may be effected by the consent in writing of the holders of a majority of the
total voting power of the Class&nbsp;B Common Stock entitled to vote thereon, voting together as a single class in lieu of a duly called annual or special meeting of holders of Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deterring hostile takeovers or delaying or preventing changes in control of the Company or our
management, such as a merger, reorganization or tender offer. These provisions are intended to enhance the likelihood of continued stability in the composition of our Board and its policies and to discourage certain types of transactions that may
involve an actual or threatened acquisition of our Board. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions are also intended to discourage certain tactics that may be used in proxy
fights. However, such provisions could have the effect of discouraging others from making tender offers the Class&nbsp;A Common Stock and, as a consequence, they also may inhibit fluctuations in the market price of the Class&nbsp;A Common Stock that
could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DGCL
Section&nbsp;203 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the DGCL regulating corporate takeovers. In general, those
provisions prohibit a Delaware corporation, including those whose securities are listed for trading on Nasdaq, from engaging in any business combination with any interested stockholder for a period of three years following the date that the
stockholder became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction is approved by the board of directors before the date the interested stockholder attained that
status; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such time the business combination is approved by the board of directors and authorized at a meeting
of stockholders by at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Dissenters&#146; Rights of Appraisal and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, including the circumstances where the Shares are, at the effective date of a merger or consolidation,
either listed on a national securities exchange or held of record by more than 2,000 holders, our stockholders will have appraisal rights in connection with a merger or consolidation the Company. Pursuant to the DGCL, stockholders who properly
request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Derivative Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action,
provided that the stockholder bringing the action is a holder of Shares at the time of the transaction to which the action relates or such stockholder&#146;s stock thereafter devolved by operation of law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exclusive Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Amended and Restated
Charter provides that unless we consent in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of
Delaware) shall be the sole and exclusive forum for any (i)&nbsp;derivative action or proceeding brought on our behalf, (ii)&nbsp;action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us
or our stockholders, (iii)&nbsp;action asserting a claim arising pursuant to any provision of the DGCL or the Amended and Restated Charter or Amended Bylaws, or (iv)&nbsp;action asserting a claim governed by the internal affairs doctrine. This
provision does not apply to any actions arising under the Securities Act. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to the forum provisions
in the Amended and Restated Charter. However, the enforceability of similar forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of
provisions to be unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The DGCL authorizes corporations to limit or eliminate the personal liability of directors and officers to corporations and their stockholders
for monetary damages for breaches of directors&#146; and officers&#146; fiduciary duties, subject to certain exceptions. The Amended and Restated Charter includes a provision that eliminates the personal liability of directors and officers for
monetary damages to the corporation or its stockholders for any breach of fiduciary duty as a director or an officer. The effect of these provisions is to eliminate our rights and those of our stockholders, through stockholders&#146; derivative
suits on our behalf, to recover monetary damages from a director or an officer for breach of fiduciary duty as a director or an officer, including breaches resulting from grossly negligent behavior. However, exculpation will not apply to any
breaches of a director&#146;s or officer&#146;s duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or for any transaction from which such director or officer derived an improper
personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Amended and Restated Charter generally provides that we must defend, indemnify and advance expenses to our
directors and officers to the fullest extent permitted or required by the DGCL. We will also be expressly authorized to carry directors&#146; and officers&#146; liability insurance providing indemnification for its directors, officers and certain
employees for some liabilities. We believe that these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The limitation of liability, indemnification and advancement provisions in the Amended and Restated Charter and the Amended Bylaws may
discourage stockholders from bringing a lawsuit against directors or officers for breach of their fiduciary duties. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even
though such an action, if successful, might otherwise benefit Cibus, Inc. and its stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for the Class&nbsp;A Common Stock is Broadridge Corporate Issuer Solutions, LLC. The transfer agent&#146;s
address is 1155 Long Island Avenue, Edgewood, NY 11717. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_8"></A>DESCRIPTION OF DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer depositary shares (either separately or together with other securities) representing fractional interests in our preferred stock
of any series. In connection with the issuance of any depositary shares, we will enter into a deposit agreement with a bank or trust company, as depositary, which will be named in the applicable prospectus supplement. Depositary shares will be
evidenced by depositary receipts issued pursuant to the related deposit agreement. Immediately following our issuance of the preferred stock related to the depositary shares, we will deposit the preferred stock with the relevant preferred stock
depositary and will cause the preferred stock depositary to issue, on our behalf, the related depositary receipts. Subject to the terms of the deposit agreement, each owner of a depositary receipt will be entitled, in proportion to the fraction of a
share of preferred stock represented by the related depositary share, to all the rights, preferences and privileges of, and will be subject to all of the limitations and restrictions on, the preferred stock represented by the depositary receipt
(including, if applicable, dividend, voting, conversion, exchange redemption and liquidation rights). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_9"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of our Class&nbsp;A Common Stock, Preferred Stock or any combination thereof. Warrants may be issued
independently or together with our securities offered by any prospectus supplement and may be attached to or separate from any such offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into
between us and a bank or trust company, as warrant agent, all as set forth in the prospectus supplement relating to the particular issue of warrants. The warrant agent will act solely as our agent in connection with the warrants and will not assume
any obligation or relationship of agency or trust for or with any holders of warrants or beneficial owners of warrants. The following summary of certain provisions of the warrants does not purport to be complete and is subject to, and is qualified
in its entirety by reference to, all provisions of the warrant agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the prospectus supplement relating to a
particular issue of warrants for the terms of and information relating to the warrants, including, where applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of securities purchasable upon exercise of the warrants and the price at which such securities may be
purchased upon exercise of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants commences and the date on which such right expires (the
&#147;Expiration Date&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the United States federal income tax consequences applicable to the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the warrants outstanding as of the most recent practicable date; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the warrants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants will be offered and exercisable for United States dollars only. Warrants will be issued in registered form only. Each warrant will
entitle its holder to purchase such number of securities at such exercise price as is in each case set forth in, or calculable from, the prospectus supplement relating to the warrants. The exercise price may be subject to adjustment upon the
occurrence of events described in such prospectus supplement. After the close of business on the Expiration Date (or such later date to which we may extend such Expiration Date), unexercised warrants will become void. The place or places where, and
the manner in which, warrants may be exercised will be specified in the prospectus supplement relating to such warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the
exercise of any warrants, holders of the warrants will not have any of the rights of holders of securities, including the right to receive payments of any dividends on the securities purchasable upon exercise of the warrants, or to exercise any
applicable right to vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_10"></A>DESCRIPTION OF SUBSCRIPTION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus may issue subscription rights to purchase common stock, preferred stock or any combination thereof. These subscription rights may be
offered independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the subscription rights in such offering. In connection with any offering of subscription rights, Cibus may
enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any subscription rights Cibus offers, if any, will, to the extent applicable, include specific terms
relating to the offering, including some or all of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price, if any, for the subscription rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price payable for Cibus&#146;s common stock or preferred stock upon the exercise of the subscription
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subscription rights to be issued to each stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares and terms of the common stock or preferred stock which may be purchased per each
subscription right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which the subscription rights are transferable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the subscription rights, including the terms, procedures and limitations relating to the
exchange and exercise of the subscription rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the subscription rights shall commence, and the date on which the
subscription rights shall expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which the subscription rights may include an over-subscription privilege with respect to
unsubscribed securities or an over-allotment privilege to the extent the securities are fully subscribed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the material terms of any standby underwriting or purchase arrangement into which Cibus may enter
in connection with the offering of subscription rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description in the applicable prospectus supplement of any
subscription rights Cibus offers will not necessarily be complete and will be qualified in its entirety by reference to the applicable subscription rights certificate, which will be filed with the SEC if Cibus offers subscription rights. You are
urged to read the applicable subscription rights certificate and any applicable prospectus supplement in their entirety. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_11"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Cibus may issue units comprising one or more securities described in this prospectus in any combination (but not securities of third parties)
as specified in a related prospectus supplement or a free writing prospectus. Units may be issued pursuant to the terms of a unit agreement, which may provide that the securities included in the unit may not be held or transferred separately at any
time or at any time before a specified date. A copy of the forms of any unit agreement or unit certificate, as applicable, relating to any particular issue of units will, if applicable, be filed with the SEC when Cibus issues units, and you should
read those documents for provisions that may be important to you. For more information on how you can obtain copies of the forms of the unit agreement and the related unit certificate, see &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, Jones Day, New York, New York, will pass upon the validity of the
securities covered by this prospectus. Any underwriters or agents will be advised about other issues relating to the offering by counsel to be named in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The financial statements of Cibus, Inc. (formerly Calyxt, Inc.) appearing in Cibus, Inc.&#146;s Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K/A)</FONT> for the year ended December&nbsp;31, 2022, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory
paragraph describing conditions that raise substantial doubt about Cibus, Inc.&#146;s ability to continue as a going concern as described in Note 2 to the financial statements), included therein, and incorporated herein by reference. Such financial
statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Cibus Global, LLC as of December&nbsp;31, 2022 and 2021, and for the years then ended, incorporated
by reference in this Prospectus and in the Registration Statement have been so incorporated in reliance upon the report of BDO USA, LLP (n/k/a BDO USA, P.C.), independent auditor, incorporated herein by reference, given on the authority of said firm
as experts in accounting and auditing. The report on the consolidated financial statements contains an explanatory paragraph regarding Cibus Global, LLC&#146;s ability to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at www.cibus.com. Our website is not a part of this prospectus and is not incorporated by
reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some
information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and the
securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to
these filings and the exhibits attached thereto. You should review the complete document to evaluate these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885907_15"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We &#147;incorporate by reference&#148; into this prospectus documents we file with the SEC, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Some information contained in this prospectus updates the information incorporated by reference, and
information that we file subsequently with the SEC will automatically update this prospectus. In other words, in the case of a conflict or inconsistency between information set forth in this prospectus and information that we file later and
incorporate by reference into this prospectus, you should rely on the information contained in the document that was filed later. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In
particular, we incorporate by reference into this prospectus the documents listed below and any filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the initial filing and prior to effectiveness of the
registration statement that contains this prospectus and prior to the time that all the Class&nbsp;A Common Stock offered by this prospectus have been sold by the selling stockholders as described in this prospectus (other than, in each case,
documents or information deemed to have been &#147;furnished&#148; and not &#147;filed&#148; in accordance with SEC rules) or such registration statement has been withdrawn: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523058346/d425657d10k.htm">Form
 10-K</A> for the fiscal year ended December 31, 2022, filed with the SEC on March 2, 2023 (as amended by Amendment No. 1 on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523060159/d472987d10ka.htm">Form <FONT
STYLE="white-space:nowrap">10-K/A</FONT></A>, filed with the SEC on March&nbsp;3,&nbsp;2023), including information specifically incorporated by reference into the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (as amended on
Form 10-K/A) from our <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523076244/d395028ddef14a.htm">definitive proxy statement</A> for the 2023 Annual Meeting of Stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended
March&nbsp;31,&nbsp;2023 and June 30, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523130564/d478119d10q.htm">May&nbsp;3,&nbsp;
2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000162828023028741/cbus-20230630.htm">August 10, 2023</A>, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and Form
<FONT STYLE="white-space:nowrap">8-K/A,</FONT> as applicable, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523008913/d451090d8k.htm">January&nbsp;
17, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523072726/d463774d8k.htm">March&nbsp;16,&nbsp;2023</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523085686/d482367d8k.htm">March&nbsp;30,&nbsp;2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523095254/d423369d8k.htm">April&nbsp;7,&nbsp;
2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523102018/d495800d8k.htm">April&nbsp;14,&nbsp;2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523110595/d381935d8k.htm">April&nbsp;
21, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523112965/d496483d8k.htm">April&nbsp;24, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523137115/d383026d8k.htm">May&nbsp;
5, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523139545/d680388d8k.htm">May&nbsp;9, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523147101/d491267d8k.htm">May&nbsp;
17, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523149284/d464760d8ka.htm">May&nbsp;19,&nbsp;2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523149295/d446878d8k.htm">May&nbsp;
19, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523154241/d509818d8k.htm">May&nbsp;25, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523158545/d487053d8k.htm">June&nbsp;
1, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523166261/d477496d8k.htm">June&nbsp;
14, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523178748/d450252d8k.htm">June 29, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523178745/d524048d8ka.htm">June&nbsp;
29, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000162828023032540/cbus-20230914.htm">September 19, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000162828023034605/cbus-20231018.htm">October 18, 2023</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1705843/000119312523263032/d485608d8k.htm">October&nbsp;25, 2023</A> (in each case, excluding any information furnished and not filed with the SEC); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our Class&nbsp;
A Common Stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312517231512/d433769d8a12b.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed on July&nbsp;20, 2017, as the
description therein has been updated and superseded by the description of capital stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1705843/000119312523178748/d450252dex991.htm">Exhibit 99.1</A> to our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on June 29, 2023, including any amendments or reports filed for the purpose of updating the description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed to be modified
or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes that statement. Any statement so modified
or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">You may request a copy of
the registration statement, the above filings and any future filings that are incorporated by reference into this prospectus, other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing, at no
cost, by writing or calling us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6455 Nancy Ridge Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego, CA 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone:
(858) <FONT STYLE="white-space:nowrap">450-0008</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g885907g27z30.jpg" ALT="LOGO" STYLE="width:3.4126in;height:0.819831in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>3,000,000&nbsp;Shares of Class&nbsp;A Common Stock </B></P>
<P STYLE="font-size:130pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:130pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Roth&nbsp;Capital&nbsp;Partners </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>A.G.P. </B></P>
<P STYLE="margin-top:130pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;18, 2024 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>d885907dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that
offering is $13,800,000. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g885907g27z30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g885907g27z30.jpg
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@ ]@0  P$B  (1 0,1 ?_$ !P
M 0 # 0 # 0             &!P@% @,$ ?_$ %(0  $# @($!PH+!@,'! ,
M   ! @,$!081!Q(A,1,V05%A<8$(%")S=)&AL;+!%3(W0E)B<H*2L\(7(S55
MT=(SHN$6)"5#1%.4-%23\&2#XO_$ !H! 0 " P$                $!0(#
M!@'_Q  S$0$  @$"! 0$!00# 0$      0(#!!$2(3$R!3-!<1-188$4(I&A
ML14C0E+!T?#A8O_:  P# 0 "$0,1 #\ U2
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MBVI:+QQ0  R9
M
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M4,CES>QG!.ZVKEZD0TZ"\UM;%/HU:.TUF<<NX "S3P
M
M
M                     'QU5JM]6[6JJ&FF?])\37+Y\CSI*"CH\^]*6"#/
M?P<:-S\Q](,>&-]]GG#&^^P #)ZJ32G"D>)&/3_FP-<O6BN3W(2;1/*KK#4Q
MK\RH7+M:TC^EER+?:5J;TID5>USCMZ)&JEHK7\BSY>9J?U*K%RU<[?578^6I
MG9.@ 6JQ
M
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MIL\^1$R:'-CY[;^S?34X[^JPP>$$T51"R6"1DL3TS:]CD<CDYT5#S(C>
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MMFM:;C356S-6L?X2=;5VIVH1[X,F/NKLVURTOVRZ@ -3,
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MS#%NN52R..:ICUW-CSU47-4V9]1V2%:LUF8GT2(G>-X  >/0
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MNQB/$UWQ%4<+=ZV2=$7-L>>3&=34V)ZSC@%M6L5C:L($S,SO( #UX
M [F&L5WG#<R/M-;)&S/-T+O"C?UM79V[S1NC/%K\86.2LGI6T\\,O O1CLVN
M7)%S3E3?N,K&@.YTXK7+RU?8:5OB.*GPYOMS3-)>W'P[\EK  HEF
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M_, !.2P            !C_%_&R]^73_F..2=;%_&R]^73_F..2=93MA16ZR
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M;+)( .K40:LT5_)]9/$?J4RF:LT5_)]9/$?J4K/%/+CW3-%WS[)4 "C68
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M) !U:B#5FBOY/K)XC]2F4S5FBOY/K)XC]2E9XIY<>Z9HN^?9*@ 4:S
M  <''_$B_>12^RID<UQC_B1?O(I?94R.7?A?9;W5NM[H  6B$U;HL^3^Q^(]
MZDI(MHL^3^Q^(]ZDI.5S>9;WE>8^R/8 !J9@          \97:D3W)O:U5,6
M/<KGN<JYJJYJ;4<B.:K5W*F2F,;A3NI*^IIWID^&5T:HO.BJGN+?PK_/[?\
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M(C43)$3D/TY;+DG)>;SZKRE(I6*P  UL@
M  *=TE\:Y_%L]1<13NDOC7/XMGJ(/B'E?=$UOE_=%0 4JJ"_['2]Y6:BILLE
MCA:U>O+;Z2C;+3]]7>B@RS229C%ZE<F9?Y:>&U[K+#0UZV  6BP
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M+/D_L?B/>I*3E<WF6]Y7F/LCV  :F8          !F#3)9G6C'-:Y&Y05O\
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M7YW.=.C<.W6HRVR521Y_98B_J(VNMPX+-VEC?)"V@ <XMP
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M=/74S*BBGBJ('IFV2)R.:O:A[SE\V2V2\VMU76.D4K%:@ -;,
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MYQSM/1L8''PC?Z;$MBIKE1[&R)D^//-8WIO:O_W=DIV#G;5FL[3U6T3$QO
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MHFQ9_M1AQ.^7HMQH\HJCG=]%_:B+VHI2:_213^Y3IZK+2YYM^2W5-@ 5::
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M-#+)2,E)I/J\I;@M%H;3!Z+?4MK*"FJ6?%FC;(G4J9GO.3F-EZ
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MD:K7M7)S7)DJ+S*?AT"J>44CXI&R1/<R1JHYKFKDJ*G*BEHX5TR72W1LI[W
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MJ$E1BY.3)45O6BGWEM%HM&\+&)B8W@ !Z]             &/\7\;+WY=/\
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M=0TMMHHJ2@@C@IHDU61L3)$0^@%/GU-\\[V3\6&N*/R@ -#:
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MM3-SOM.7:O:ITRKU'B%LD<-.4?NG8=+%.=N<@ *Y+
M                                     #TUE)!6T[X*N)DL+M[7IF@
MF-^4DQN@EXT<Q/<Z2U57!<O!3)FB=3DV^L@EUM,]LE6.=\3E3Z"JOK1 "GUF
M&E)WK&RLU6*M.V$ZT34#V15E<KVZDF4;6IOS3:JJ6$ 3]'&V&J9I8VQ0  DM
MX
M                                                          __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g885907g57l88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g885907g57l88.jpg
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M 0 # 0$!               #! 4& @'_Q  R$0 " @$!!@4"!@(# 0
M 0(#!!$%$B$Q,W$3,D%1810B(U*!D<'P0J$5L='Q_]H # ,!  (1 Q$ /P"U
M(                                !&.+\<5$E3+26:3@H&+JNG;])Z_
MA7B3GWD@7Y[XK'<'Q9\(VGD5N7+JJ0"9V?=*"48\-2EF6RAI&/J>D\TL\BOG
MD?(]=[GN557K4R;==*ZVR(^AJI853B:[8O2FY3"-A8+8^\7:GH8WZBRJN;\L
M]5$3-5RZC*CO.2W>9G1U;X<R3L&8OCO.5)6HV*O1-F6QLJ<W(O,=<0IB7#]7
MABM@D9,KXW+K13L355')Q*G$I*>$[PV]6:&J7))D\25J<3TW]N_K-G%NDVZK
M/,C4Q[9-NNSFC<  NEH
M
M                               _'M:]CFN1%:Y,E1>-"&L6X5J;-522
M0QOEM[ES9(U,]1.1W)T\9,P(+\>-ZT?,ANI5JT97,DK1C8)Z>62Z5D;H]9FI
M"UR9*J+O=EU9)TJ=VVBI62<(VF@;)]Y(T1>T]RO1@JN6])ZZ$-6(H2WF]30X
MYMZ7##58W+.2%O#,7D5NU?9FG6<9HGKECNE51.7Q)H]=$_$U?Y*O82?*Q)(G
MQNW.:K5ZR&, N6'&%$G*Y[%_=<?,C[+X37KP_O[GR_[;H21-( - N@
M
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M,6[J2[G7:(_.)9?6.[CBU!5?1'YQ++ZQW<<6H,G:?47;^67L+R/N  9I<
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M'R*9@ ZXP2>_!R^H+M^E-[J$MD2>#E]07;]*;W4);.:S>O(V,;I(  JDX
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M:O0S$M7H3CAND^0V*@I\LE9"W6])4S7VJIL0#IHK=22-Z*T6@ !]/H
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MJ,;HQ[(Q;NI+N==HC\XEE]8[N.+4%5]$?G$LOK'=QQ:@R=I]1=OY9>PO(^X
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M:6I@JX&34LT<T+TS;)&Y'-7H5#$LIG4])K0T861GQBSU !&>P
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M3XYD_84Q-;<46_Y7:IM;+))(G;'QKR.3X[E,/:$+7/>DN'H:6)*O=W8\S=
MS2X            5ITZ><*J]3%W2/R0-.GG"JO4Q=TC\ZC&Z,>R,6[J2[G7:
M(_.)9?6.[CBU!5?1'YQ++ZQW<<6H,G:?47;^67L+R/N  9I<   !BW?ZJK?4
M/[JF48MW^JJWU#^ZI]CS/CY%,P =<8)/?@Y?4%V_2F]U"6R)/!R^H+M^E-[J
M$MG-9O7D;&-TD  52<         \*^CI[A134E;$V:FF:K'L<FQR*5MTCZ.Z
MW"\\E51M?4V=RYME1,W1?A?_ #W+S%F3\>QLC',D:CF.3)6JF:*G(6<;)ECO
M5<O8ANIC:N/,I4"P>,M#]NN;I*FP2-MU4NU853.%R\W&WJS3F(:Q)A"]X=>O
MY4H)61(N23L37C7]9-G4N2F[3EUW>5\?8S+*)U\T:$V=CO\ =;%/PMHKYZ5V
M>:HQWBNZ6KL7K0U@+#BI+1D2;7%$VX2TTHY64^)Z5&\7RJF39TN9\4["7[7<
M:.ZT;*NW5,533O\ HR1NS3HYEYBF9NL*XGN>&*]*FU5"L15^<B=MCD3D<GQW
MF;?LZ$N-?!_Z+=67*/"?%%O <S@/&-!BZV\-2_-5<>23TSES<Q>5.5J\2G3&
M+.$H-QDN)I1DI+5  'D^@        %+:J)8*F:)=\;U:O4N1YF_Q_0K;L:WJ
MF5,D2J>]J?A<NLGL5#0'6PEO14O<P9+1M$Q^#?.C:^^0*NU\43T_55R+WD)S
M*T:#KFEOQY3QO=DRLB?3KGRKDY/:U$ZRRY@[1CI<W[FIB2UKT]@ "@6@
M                    0GCWRMN/I-[B$V$)X]\K;CZ3>XAG[1Z:[E/-\B[G
M/G3Z-O*VE]%_=4Y@Z?1MY6TOHO[JF;C]6/=&?3U(]R90 =$;@
M *I:4O.!?/7_  0M:52TI><"^>O^"&GLOJ/L4LWR+N<L;7#5@K\1W+Y#:F,?
M4:BR9/>C4R3+/:O2:HD?0%Y>?LDGO::]\W77*2]"A5%2FHLQ_P T6+/\I3_\
MAIY3:)\71IFVWQR>A41_%4+. QO^3N]E_?U-'Z.OY*BW;"5_M+'/N%HK(HV[
MY.#5S$_63-/::,NL1WI$T:6^_P!)-56J&.DN[45S58FJR9>1R;LU^]VEFG::
MD]+%I\D-F&TM8,K:;?"N(*[#5WBN%ND5'M7)\:KXLK>-KN8UE1#)33R03L='
M-&Y6/8Y,E:J+DJ*>9IM*2T?(I)N+U1<3#=ZI<066FN5"[.&9N>JN]CN-J\Z*
M;(@;P>[^Z"ZU=CF?\S4M6>%%7=(WZ2)TMV_JD\G-9-/@V.'H;--GB04@ "N2
M@        %:=.GG"JO4Q=TC\D#3IYPJKU,7=(_.HQNC'LC%NZDNYUVB/SB67
MUCNXXM057T2;-(EES_Q'=QQ:@R=I]1=OY9>PO(^X !FEP   &+=_JJM]0_NJ
M91B7A<K37*NY(']U3['FCX^130 '7&"3WX.7U!=OTIO=0ELB3P<OJ"[?I3>Z
MA+9S6;UY&QC=)  %4G            !^/8U[',>U'-<F2HJ9HJ'Z #@L3Z*\
M/7K7DIX5MM4[;PE,B(U5YV;NS(AK&.C>]X:1\[HTK:!NWY1 BKJI^)N]OM3G
M+1!4145%3-%XBY3G6U<&]5\E>S&A/X92D$TZ8-'$$%-/?;!"D;6>/54S$\5$
MXWM3BRXTZR%C=HOC='>B9EE;KENLVN&+Y5X=O-/<:!^4D2^,W/9(WC:O,I;.
MQ72GO5HI+C1.UH*B-'MY4Y47G1<TZBFY.W@[7ATUMN5HE=G\G>D\2+]UVQR=
M"*B+^L4MI4J4/$7-%C#LTEN/U)@ !AFF         5^\(.SK2XDI+HQOS5;#
MJ.7\;-G=5O8I%1:G2EAU<280JJ>%FM60?/T_*KFY^+UIFG2J%5E14545,E0Z
M'9]OB5:>J,G*ANSU]SVHJF6BK(*JF=J302-D8[D<BYHI;W#%Y@O]BH[G3*FI
M/&CE;G]!VYS>I<T*>$EZ%\:ML%R=:[E)JVRK?FU[EV0R;L^A=B+U+RGS/QW;
M#>CS1]Q;=R6CY,L6 FU-@.?-4                        $)X]\K;CZ3>
MXA-A">/?*VX^DWN(9^T>FNY3S?(NYSYT^C;RMI?1?W5.8.GT;>5M+Z+^ZIFX
M_5CW1GT]2/<F4 '1&X            "J6E+S@7SU_P $+6E4M*7G OGK_@AI
M[+ZC[%+-\B[G+$CZ O+S]DD][2."1] 7EY^R2>]IJ971EV*5'418\ ',&T
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MN>A1I:4TV6F!'?YX<*_XE9_L+_,^9-,>%VMS:M<]>1L'\U.?^EN_*S6\>O\
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8R-J-:G4AZ@$!(               ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g885907g72e66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g885907g72e66.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[14Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %1Z^5 8X0DE-! 0      " < 5H  QLE1QP"   "   < E  #$MU<W5M
M($UO=7)Y83A"24T$)0      $$7N]""+/(U"/ SE? .SKXHX0DE-!#H
M .\    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      !  E,S,  $  @"4S,P  0 ".$))300F       .
M         #^    X0DE-! T       0   !:.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!$0      !     "   "0    D      .$))300>
M   $     #A"24T$&@     #0P    8              #P   #V    !P!0
M $$ 1P!% #  ,  Q     0                         !
M  #V    /                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    /     !29VAT;&]N9P   /8    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   #P     4F=H
M=&QO;F<   #V     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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MHK*#!R8UPM(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%Q@C43(9)C9"87&!)"4G*"DW.$5'=G>AL?_$ !T!  (#  ,! 0
M   (!08' 0,$ @G_Q !-$0 " @(! P,# 00$!PD1   ! @,$!1$ !A(A!Q,Q
M%")!42,R88$5%B1Q""4T-D-BD35"1$5UH;&UT28G,S=&4E-4569R<W2"DK3!
M_]H # ,!  (1 Q$ /P!_C1PX:.'#1PX:.'#1PX:.'#1PY53U5KWF:EXUH*>.
M9&P0%+FIF<:Y$L-;6=L7J"Z2$2-4B'LJQ%-U'1<N9:=%<A5TT)%PR;-')@+Z
M:#K&/6?(Y^AB,:,5-:JT)[%A<K:J-)&ZE4A-."6>+3Q03]UGO4.HF:-(V.OL
M?+O5&]F*6-H_T=)8@IS2SKD)ZY=&5@(?I8GFCU)%%+W6"=?:[(JN0 %>&>SR
MX;@\+XR4W.R-JG)G C'(4;3+S0I]Q+/RN*Q*N8^/D<CU47RJR#9>!G9=DT$T
M>FW]YN&[]B]<G0;+E2H70M_JC 8<]837+-CII,I#0R6-M&>4O2F,,4N5I&1F
M56K6IT3]D%]YQ-'*^HV"T_I&YG\/C#U*]J:? ID(J=VC,\K]U:9HXY,A5]S:
M(U>>>--QZ]YD>.1@JMVL/IJ)K)IJI'(JDJ0JB2B9@.FHF<H&(<ARB)3$.40,
M4Q1$#%$! 1 =-&K!E#*0RL RL#L$$;!!'@@CR"/D<8 $$ @@@C8(\@@_!!_(
M///7/.>&CAPT<.&CAPT<.&CAPT<.&CAPT<.&CAPT<.&CAPT<.&CAPT<.&CAP
MT<.&CAPT<.&CAPT<.&CAS'+9<*E0H"0M5YM%>IM8B4O7E+%:9F.@(..1^7J/
M965<M&+4@CX RRY ,;@I>1$ UZ*M2W>G2K2K6+EF4ZCKU89+$\A_1(HE=V/_
M ,*GG38LUZD3V+4\-:",;DFGD2*)!^K22%57]/)&SXY7)>.LCT[*,^6C7&?F
M]F>MU?26+2*7?+4Q >XQ141G(VMGK[Q+DHB4[*6<@H40,EZ@#SK0Z7I!Z@W8
MQ*N!:LC?'UMRC5D'C?W0RV!.GY![XUT1HZ/CE-M^HW2%1BC93WW! U5JVIAY
M.O$@A$3#\_:YWHZV01S.,2]5'8-F>1:0M2W&5",G'IRI-XB_-)[&RZSA00*D
MV;O+U$P,0]<K'$$T$&$DZ474$$TBG4$"CX<KZ8==8:-YK?3UN6",%FFHM#D5
M"CY=DI2SS(H'EFDC0*/+:'GGJQ_7?2>2=8J^9KQS/KMBM++3))) 4/9CBB9B
M00 DC;((&SRP--1-9--5)0BJ2I"J)*IF*=-1,Y0,11,Y1$IR'*(&*8HB4Q1
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MUNOW"JRK2<K%JA(JQUV;8*"JQEX*;8H2<3*,U1 HJ-7[!RW=-SB4HF25(80
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MEN4D5U#@(!4\]TIU%TQ(D>=Q-K'^Z2L4L@22M*R^2L5J!Y:TC >2B2E@OD@
M[Y8<3U#A<ZC/BLA!;* -)&I>.>-3X#25IECG12? 9HPI_!/)&:KW)GD:L][H
M:-@5S#PDG&RMMN4['KS;:KPDI3:^E#UAK),85Q<;I<,AVBF42D5,LY*1L$TD
M['96;J<G'R$-68Z<E 69I6/!=,W<ZLTT<D52G XB:S-%;G,UDQ/.M.G4H5K=
MV[;,$<D[15Z[+#!&TUF2&+M8PF7SM7$M%$\<EFS,IE6O#)6B]N!72)K5FQ<G
MK5:M82R1Q"2>93+*ZQ0K+)M1[,%[G*5G%[*UUK$S-+O,-$M+&O4;#(5&;]\U
M!^\<1;*\TFVT"S7&C7JF.)=F]AE9BMV1ZO$2[4\58X^$D56S1;C.=-7,(D5A
MIH;M*:5ZZVZ\=N#V;<:+(]*[4OUJEVC<6)TF$-FN@EB82UWFC!<<XK.5LHSP
MB.6K;CC6<UIWK2F2N[%%M5IZD]FK:K&0-$989F[)%[)5C9E#<=O W9XSV8X4
MG\RY+64<HM%"0]2JC%=%&:O-Q?(.%8FLQ!E^Y-$RY6SA[*2*B:J,/"LI"440
M<BU(T<=G2/2N1ZQS5?#XX!"_[6W:<$PTJ:,HELR@:+=O<J11 @RS.D89 Q=?
MGJ+/T^F\7/DKA+!-)!70@26K#[]N&/?QL@M(Y!$<:NY#=H4I0W[*N]CJT9_:
MU]DSG+W+.'+I[5<8UMPK&8SQ?7R*E06D5?;'*</#,VB;A!O+7"R.32TNX4;-
M57SE92+C2.71Q?1GI3@I+#O!2B54CLY*R@ER62G*DB,%%:::1M.8JE91%$H9
MQ&H$LG%HLY#J;K[*QQHDUN1F9X:4#&*E2B^T$L'8)%&NT$L\^Y'8A2S$JIM,
MQQ]G"M\A"M7F6MSD!69U1(AW,!0L=/K@P:JF+W>F-FGK33U7(HB/:<J=;23.
M<!%-<4^WNS')?X0]1)73%=-3680=+8OY!*KNNM$FM!6M@=VAHM9)  [EWX%[
MI>C=EHU:]G(H)=]S15*;64!!VH]^66HY !^%B7[CL'6^[2^X;[/GN)QS"/K)
M@S(M5SXA')*.5JLXAU,;7I=$A/4.2#8R,U8ZU+JI$*IRV6L\0[="":4>Q=.%
M2MPF>G_7SI_(SQU\YCK.":0J@M)*,A14EM;G=(8+,2ML#8K2J@[BSJOW<B\S
MZ29BE"\^*N0Y;L!<P>W]':.AY$2-)-#)H _:)HW8]H1'8*.7;]%:.N<%L4J]
M8OS*S1-FJ>1<G5I]!6Y&29S=>"*LBB1(-Q'2Q4WD65AW&(2..B@5MW& J)1,
M(CC'K+)3GZXLV:#UY:UK'8NQ'/5,;0V!)57]LKQDI)W@#[P3O7DDCFG>FB68
M>E:\%M)XIJ]R_"T-E9$FA[+#?LF20!D["2.PJNO/@<MEUE7+]PT<.5-]7U!(
MV",<N!(7UT\MLT$U1 HG(DXIMO,LF41\@54S=$3@ @413*)@$0#C%/7-5_JU
MBW('<N;C4$@[[6H7BP!'X+*A(_)4?&M\RKU:53@\<Q4%AED"^!O34[9(!/D;
M**21^GZZY%S:=DB7W!5_:OMI>NEW[;&>7+'D6XF<B90Q:#C..C+#1&#TX<F7
MC9"QV20KJ+8WZ3=**C$A'T4DP3IW1.5GZFJ=%](RL\BXC-7,ID.[;?XLP\45
MG&QR,1]\,MRX]15.@JUXO':$(K/2F1ES]?I;IV0F5,;EK61MEMG5#&Q1V*"N
M23WQO8MO75?"H(8U* * K ^F<YO?#1PX:.'.N,O= <Y9WOW'%K*10AG>2MUE
MBQ^SF'*"KEM&.;GEUY7D)-TU14(JY;,5I$CI=%-1)50B)R$5(=0.W]#:-],7
MT54RCQ&5,=TM7OM&I"R2K4Q*SL@+!@"XB[48@C[B2&T!Q.+51KW4UB@C!'NY
M^>L'(=HX_J+XA#%>Y?MC+[?7:?'AMD'EA>Y_H7[F-O6,;)E>N72C9DKM*B7<
M[;(BM(3L%;X^"C4E'<I-L(.3;N(Z88Q#)-=[)(MI<DH1HDHJSC'P%5!.@=->
MMW3>?R57%V:=_$V+<B5ZTMEH)ZDD\K*L<,D\;"6)Y7(2,M"8V8J))$V";?F_
M2[-8>C/>AL5,C7KH9;,</NPSI#&&+RK%(K1NL2;9R).]%[W6,_"S_P"@YORN
M]]D9_:!ENR/[0I UA>VX9L$X\6?2S6'A%VC2Q4!:0<G4<R#%@U>-INKIK&.I
M$QS&?CBN#1B$,R8T/URZ&I44AZMQ-:.JL]I:F8KP*%A::=6>O?6-?MC:1D:"
MR0%621H)"/=DD=[7Z5=56;+2=.WYI)S%"\^-EEVSK'$0)J9D))8(K"6%6/<B
M"1 ?;6-59ITMO-MX:.'#1PX@1U?/'4<W-]H%'FQTP?/!>#?A72/("(<&$0[@
M$.[GD #CX@X>_P!(SKT[Z:_^1?UK?R<M?^=;/\_@'>]:'%/]0P3UCG#L?^%J
M_(^ ,?5)[2?MV>[978.P.WR?+YM%_H13?^U:]_9_RAG_ '__ '2-7O\ +;GG
M?]JL>?U_;/Y_GQIZ9W4JD'>ZT!W^O[)?/X_Z!S*M>7GIXD7U\B ;?P\ 3  #
MAW&X#R \B7U+"80 1Y#D>WSQ\O'(?Q#ITO0G_,1/^5\B//@?$'\/@[UY_/\
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M;DVW=BY4RV)%5X? X'/=;99IYY+$L,LHDOY:P"R1JI^Z-2ZE)9 H$<%:+48
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M@2D$*QPH2-E(UWYWQI\1C(,-C*6+K;]FE72%6/[TC#[I)6\G[YI6>5P#H,Y
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M P*L 5((((!!!&B"#X((\$'P1S@@$$$ @@@@C8(/@@@^""/!!^>5_,MJ./\
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#G__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
